

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

### EFFICIENCY OF ER:YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS: A STUDY PROTOCOL FOR A RANDOMIZED CLINICAL TRIAL

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-054523
Article Type:	Protocol
Date Submitted by the Author:	15-Jun-2021
Complete List of Authors:	Shindova, Maria; Medicinski universitet-Plovdiv, Department of Paediatric Dentistry Belcheva, Ani; Medicinski universitet-Plovdiv, Department of Pediatric Dentistry
Keywords:	Paediatric anaesthesia < ANAESTHETICS, Laser therapy < DERMATOLOGY, Child & adolescent psychiatry < PSYCHIATRY, Anxiety disorders < PSYCHIATRY



# BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright

# **EFFICIENCY OF ER: YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG** PAEDIATRIC DENTAL PATIENTS: A STUDY PROTOCOL FOR A RANDOMIZED CLINICAL TRIAL

### <sup>1</sup>Maria Petrova Shindova, <sup>2</sup>Ani Bozhidarova Belcheva

<sup>1</sup> DDS, PhD, Senior Assistant Professor, Department of Paediatric Dentistry, Faculty of Dental Medicine. Medical University Plovdiv, Bulgaria, mariya.shindova@gmail.com, Mariya.Shindova@mu-plovdiv.bg, ORCID iD: 0000-0003-2996-3700

<sup>2</sup> DDS, PhD, MSc, Professor, Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, abeltcheva@yahoo.com, vice rector ea@mu-plovdiv.bg, ORCID iD: 0000-0002-9625-8684

### **Corresponding author**

Maria Shindova, DDS, MSc, PhD Senior Assistant Professor Department of Paediatric Dentistry Faculty of Dental Medicine Medical University - Plovdiv 3 Hristo Botev Blvd 4000 Plovdiv, Bulgaria Mobile: + 359 898 390 935 email: mariya.shindova@gmail.com Mariya.Shindova@mu-plovdiv.bg

### Abstract

### Introduction

When providing dental care to children with a high level of dental anxiety, the range of approaches are divided into two sections - use of behavior management techniques and application of alternative methods for caries removal. In an attempt to reduce dental anxiety, they can be mixed and matched in accordance with the dentists' choice. Owing to the promoted advantages Er:YAG laser turns into an ideal alternative technique for hard dental tissue therapy in anxious pediatric patients. The aim of the study is to assess the efficacy of a modified version of the behavior management technique Latent inhibition in combination with Er:YAG laser for achieving reduction of dental anxiety in pediatric dental patients.

### Methods and analysis

This is a protocol for a randomized controlled clinical trial. The participants will be children aged 6-12 years, requiring conservative treatment of occlusal carious lesion on a second primary molar. Patients will be randomly assigned to the experimental or control group via a computer-generated sequence. In both groups, Latent inhibition will be used as an anxiety-management technique. In the experimental group caries treatment will be performed with Erbium:YAG laser, whereas in the control group with the conventional rotary instruments. Outcome measures will be dental anxiety felt before and after the treatment, reported by the patient on a modified version of Faces Scale by LeBaron and the dynamics of heart rate, registered during the treatment session, measured with a mobile pulse oximeter. Data will be analyzed by Independent sample t-test and paired t-test, p<0.05.

### Ethics and dissemination

The study protocol has been approved by the Committee for Scientific Research Ethics, Medical University-Plovdiv, Bulgaria (Reference number P-2839, Protocol of approval No. 3/30.04.2015) and registered on a publicly accessible database. This research received institutional funding from the Medical University–Plovdiv, Bulgaria. The results will be presented through peer-reviewed publications and conference presentations.

Trial registration: ClinicalTrials.gov (Registration number: NCT04924452).

Keywords: Er: YAG laser, anxiety, management technique, pediatric dentistry

### Article Summary

# Strengths and limitations of this study

• The study focuses on the implementation of known behavior management technique in the alternative caries treatment method resulting in a reduction of dental anxiety in pediatric dental patients.

- This is the first trial to study the efficacy of Er:YAG laser therapy in combination with a behavior management technique in reducing anxiety among pediatric dental patients.
- A key strength of this study is that all participants meeting eligibility criteria will receive active treatment.
- Both subjective and objective tools are used to assess dental anxiety in this study.
- A limitation of this study is that it is not a split-mouth design whose advantage is the reduction of the outcome variability estimation, leading to the potential increase in statistical power.
- 1. Introduction
- 1.1. Background and rationale

When providing dental care to children with a high level of dental anxiety, most pediatric dentists find the conventional rotary treatment method inefficient and uncomfortable. According to the principles of behavioral dentistry, as part of pediatric postgraduate education, the so-called `4S` principle must be adapted and modified to the individual clinical situation to provide adequate dental care to anxious pediatric patients <sup>1</sup>. The range of approaches can be divided into two sections – behavior management techniques (BMTs), on one hand, and alternative methods for caries removal, on the other hand. In an attempt to reduce dental anxiety, they can be mixed and matched in accordance with the dentists' choice.

As it has been found for more than 20 years that lasers are effective for caries excavation, Laser pediatric dentistry has been rapidly developed. It offers total innovation and changes the conventional restorative treatment in pedodontics <sup>2</sup>. Owing to the promoted advantages such as minimal intervention and prevention, safety due to the low penetration depth of the laser beam, selective removal of caries lesion, lack of thermal damage, no pain perception and use of local anesthesia, a significant decrease of patient discomfort and dental anxiety and increase of subjective acceptance and tolerance of laser therapy in children, Er:YAG laser turns into an ideal laser for hard dental tissue therapy in anxious pediatric patients <sup>2</sup>,3,4.

Based on the concepts of Minimal Invasive Dentistry (MID), the use of BMTs during the treatment of anxious children to reduce their anxiety is required <sup>5</sup>. Several specific BMTs are not part of the regular curricula of dental students and have been used by pediatric dentists only<sup>4,6,7</sup>. Such a phycological technique is Latent inhibition also known as Gradual exposure <sup>8,9</sup>. It involves a series of several positive non-painful – check-ups and preventive procedures, before any invasive or

painful dental manipulations. Step by step the child is exposed to potential anxiety-provoking procedures or instruments, resulting in an acquaintance with the dental setting and personnel, as well as being accustomed to dental treatment. Despite the specific indications, required preparation and higher time consumption, the use of this technique is very rewarding as the pediatric patient eventually becomes comfortable with the dental procedure and creates a feeling of ability to cope within the child <sup>6,7,10</sup>.

Over the recent years, dentists advance in using alternative methods for caries removal as part of their everyday practice. Therefore, the investigation of this synergetic effect of laser caries removal and the different BMTs is crucial for the present and future development of pediatric dentistry and will improve the quality of dental care.

1.2. Objectives

The aim of the study is to assess the efficacy of a modified version of the BMT Latent inhibition in combination with Er:YAG laser for achieving a reduction of dental anxiety in paediatric dental patients. The main objectives are to compare dental anxiety felt during the laser and conventional dental treatment. The outcomes will be dental anxiety assessment by self-reported anxiety scale during treatment in both groups as well as the measurement of heart rate dynamics during the procedures.

1.3. Trial design

The research is designed as a randomized parallel-group controlled clinical study. Table 1 presents the recruiting, allocation, interventions, monitoring, and analysis of the research in accordance with the Standard Protocol Items: Recommendations for Interventional Trials recommendations<sup>11</sup>. In accordance with the Latent inhibition technique patients will have two visits to the dental office – a preventive procedure, the first one, and treatment of caries lesion, the second one. Two groups will be compared. In the experimental group the enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment will be performed with Erbium:YAG laser, whereas in the control group the conventional rotary instruments - high-speed and low-speed dental handpieces, will be used for the caries treatment.

		STUDY PER	RIOD		
	Enrolment Allocation Post-alloca				
TIMEPOINT*	-t <sub>1</sub>	0	t <sub>1</sub>	t <sub>2</sub>	t <sub>3</sub>
ENROLMENT					
Eligibility screening	×				
Informed consent	×				
Allocation		×			
INTERVENTIONS					
Experimental group				×	
(BMT + Laser treatment of dental caries)					
Control group	4				
(BMT + Caries treatment with	$\mathbf{O}$			×	
conventional rotary instruments)	14.				
ASSESSMENTS	0				
Self-reported dental anxiety	1	1	×		×
Heart rate			-		-

Table 1. Trial design. The table summarises the enrolment, allocation, interventions, and assessments in the trail

\*Post-allocation time frame: t1 - before the start of the treatment;  $t_2$  - during laser or conventional treatment;  $t_3$  - end of the treatment, before leaving the dental chair.

- 2. Methods and analyses
- 2.1. Study setting

The study setting of this research includes the Department of Paediatric Dentistry and the Laser Centre of the Faculty of Dental medicine, Medical University – Plovdiv, Bulgaria.

- 2.2. Eligibility
- 2.2.1. Inclusion criteria

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright

- 1. Participants in the study are children aged 6-12 years, compliant with the cognitive development of the child;
- 2. Children, requiring conservative treatment of occlusal carious lesions on a second primary molar, without spontaneous unprovoked pain, percussion or palpation pain or other symptoms, indicating pulp involvement or periodontal pathology. Lesions are classified as a distinct cavity with visible dentin without prior restoration or sealants by the International Caries Detection and Assessment System (ICDAS) with code 05 <sup>12,13,14</sup>. Included are caries lesions only on vital teeth.
- 3. Children with one or more permanent molars giving indications for pit and fissure sealing;
- 4. Patients without previous experience with laser treatment of carious lesions;
- 5. Children who are not considered medically compromised or medically complex patients;
- 6. Verbal assent from the child willing to comply with all study procedures and protocol;
- 7. Obtained written informed consent by the patient's parent/guardian for participation in the study (see supplementary data file S1 'Patient consent form' and S2 'Information leaflet').

### 2.2.2. Exclusion criteria

- 1. Patients who were undergoing therapy with neurological, sedative, analgesic, and/or antiinflammatory drugs 7 days prior to treatment that might affect heart rate;
- 2. Children, who were first-time dental patients;
- 3. Children with systemic diseases or physiological development delays;
- 4. Children with mental or cognitive problems;
- 5. Active infectious diseases such as influenza, scarlet fever, etc.
- 6. Excluded are molars which are affected by disturbances in the development of dental structures (hypoplasia, hypomineralization, fluorosis)

### 2.2.3. Interventions

Patients will be divided into 2 groups (41 per group) – experimental and control groups. All treatments will be carried out by the same operator (MS), without anesthesia. A baseline dental self-reported anxiety will be recorded using a Faces anxiety scale as well as the dynamics of heart rate, measured with a mobile pulse oximeter.

### **BMJ** Open

### Er: YAG laser therapy protocol (experimental group):

Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment. Chosen protocol parameters are modified based on previously conducted studies <sup>2,3,4,15,16</sup>:

- preventive procedure sealant application:
- a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar;

- tooth surface will be washed for debris and organic residue removal and dried with air spray;

- isolation;
- laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 μm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm<sup>2</sup>;
- tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time;
- reisolation;
- tooth surface will be dried with air spray for 15s;
- fissure sealant application (Pit&Fisssure Sealant, DMP Ltd);
- light cured for 20 seconds.

• caries removal – parameters: enamel removal – energy 100-200mJ; density 9.84-13.03 J/cm<sup>2</sup>, pulse frequency 20Hz; tip diameter 800  $\mu$ m; water spray level 8; tip-to-tissue distance 0.5÷1 mm from the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm<sup>2</sup>, pulse frequency 20Hz; tip diameter 800  $\mu$ m; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.

### Conventional therapy protocol (control group):

- preventive procedure sealant application
- a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar;
- tooth surface will be washed for debris and organic residue removal and dried with air spray;

- isolation;

- tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time;
- reisolation;
- tooth surface will be dried with air spray for 15s;
- fissure sealant application (Pit&Fisssure Sealant, DMP Ltd);
- light cured for 20 seconds.
- caries removal conventional rotary instruments will be used high-speed and low-speed dental handpieces. Restoration with compomer.
- 2.2.4. Clinical protocol

First visit:

- 1. Parents/guardians are informed about the protocol of the study and the laser technique. They sign the informed consent form (see Supplementary data files S1 and S2). Verbal assent from the child is obtained.
- 2. Oral examination and sealant application are performed according to the assigned intervention.
- 3. Patient's self-report of dental anxiety before leaving the dental chair.

Second visit:

- Patients will be asked to report their dental anxiety, pointing to the face or choose the number which most closely depicted its state of anxiety using a modified version of the self-report Faces Scale by LeBaron et al.<sup>17</sup> (see Supplementary data file S3)
- 2. Pulse-oximeter is connected to the patient's index finger. The start of heart rate monitoring and recording will be 5 minutes prior to treatment. Time frame: at least 5 minutes after the dental treatment, before leaving the dental chair.
  - 3. Caries treatment is performed according to the assigned intervention.
  - 4. Patient's self-report of dental anxiety before leaving the dental chair.
- 2.3. Outcomes
- 2.3.1. Primary outcome measures

The primary outcome measures will be the dental anxiety felt, reported by the patient on a modified version of the self-report Faces Scale by LeBaron et al. before and after the treatment session. The scale comprises a row of five faces ranging from `relaxed` to `very worried` in combination with a

### **BMJ** Open

visual analog scale of 0 - 10. Each child was asked to point to the face or choose the number which most closely depicted its state of anxiety.

2.3.2. Secondary outcome measures

The secondary outcome measures will be the dynamics of heart rate, registered during the treatment session measured with a mobile pulse oximeter (CMS50F, CONTEC), placed on the index finger of the left hand <sup>18</sup>. Throughout the whole procedure of each dental visit, data were recorded and analyzed by a specially developed digital processing and graphic visualization software SPO2 Review V1.2 rel.

2.3.3. Participant's timeline

Each eligible patient undergoes two visits. The first appointment includes screening, consenting and assenting, recording of dental anxiety, sealant application according to the assigned interventions for each group. The second appointment at the one-week recall includes a recording of dental anxiety and treatment of a carious lesion according to the assigned interventions for each group. The manipulations will be performed by one operator.

2.3.4. Sample size calculation

The sample size calculation is performed based on data from a pilot study with 20 subjects. The sample size is calculated to assure a test power greater than 95% and a significant level of  $\alpha = 0.05$ . We estimated a sample size of 41 patients per group to detect significant differences. Thus, the final sample size for this study will be 82 patients.

2.4. Recruitment

The patients at the Department of Paediatric Dentistry of the Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, who meet the inclusion criteria, will be screened for eligibility. Once identified, patients will be informed about this research project and will receive information about the possibility of potential study participation. Patient recruitment starts obtaining the full quota of participants within a one-year time frame. It begins in September 2021 with an estimated enrollment capacity of 5 patients per month.

### 2.5. Participating centers

The patients are randomly selected from the visitors in the Department of Paediatric Dentistry of the Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, and treated in the Laser Centre of the same university.

2.6. Assignment of the intervention

2.6.1. Sequence generation

The patients will be randomly allocated to either the control group or the experimental group (41 patients in each group) according to the enrolment number in the trial. The randomization will be created using a computerized random generator.

2.6.2. Allocation concealment mechanism and implementation

A randomization list will be created by a random generator before the start of the treatment and kept in a locked drawer. Assignments will be kept in separate, closed opaque, sequentially numbered envelopes, enabling the sequence to be concealed until the intervention is assigned.

2.6.3. Blinding

The randomisation will be independent, that is, the patients and parents/guardians will remain blinded to group status. The operator will get acquainted with the procedure to be performed prior to the first session. The operator is selected to be the only one performing the manipulation to prevent bias. The statistician will be blinded to treatment assignment as data will be masked before the analysis without giving the statistician the key.

2.6.4. Data collection, confidentiality, storage, and monitoring of the study documents

Collection, coding, storage, and evaluation of personal data within the project will be carried out in accordance with The General Data Protection Regulation (EU) 2016/679 (GDPR). A prerequisite for data collection will be the voluntary written informed consent of the patient's parent or guardian. Confidentiality will be guaranteed by a coded ID number, access will be granted exclusively to the study investigators. The information from the paper forms will be exported to a database file and stored on a password-protected computer. Only the investigators and statistician will have access to the final data set. All data collected will be stored in sealed containers in areas

### BMJ Open

of the Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria with limited access.

3. Statistical methods

The obtained data will be recorded, tabulated, processed, and analyzed using SPSS (Statistical Package for Social Science software) version 21.0 (IBM, USA). In all tests, the significance level of 5% probability or the corresponding *P*-value will be adopted. Descriptive statistics will be calculated. Discrete variables will be summarised by frequencies or proportions. Continuous variables will be presented as means and standard deviations. We will compare anxiety mean scores according to the Faces Scale by LeBaron as well as heart rate mean score. Comparisons among groups will be performed by using the Independent sample t-test and paired t-test.

4. Patient and public involvement

The development of the research question and outcome measures will be based on the review of available evidence in this research area. Patients will not be involved in the development of the study protocol. However, their questions and concerns will be addressed during patient recruitment and study implementation. During the conduction of the study, patients will not be informed about the results of the ongoing trial since there is no planned interim analysis. The results will be disseminated to the study participants through email and routine follow-up dental check-ups.

5. Ethics and dissemination

The clinical study will be conducted in accordance with the conditions and principles of the Declaration of Helsinki, the existing EU Clinical Trial Directive (EC) No. 2001/20/EC, the recommendations of the Ethical Committee at the Medical University of Plovdiv, Bulgaria and the international ethical and scientific quality standard for designing, recording and reporting trials that involve the participation of human subjects - Good Clinical Practices (GCP).

5.1. Research ethics approval

The study was approved by the Committee for Scientific Research Ethics, Medical University -Plovdiv, Bulgaria (Reference number P-2839, Protocol of approval No.3/30.04.2015) and registered on a publicly accessible database ClinicalTrials.gov (Registration number: NCT04924452). Ethical approval for the study protocol and the written informed consent for all

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright

subjects' parents/guardians was granted by the Ethics Committee of the Medical University, Plovdiv, Bulgaria.

### 5.2. Consent

The operators will obtain written consent from patients' parents/guardians willing to participate in the trial. Additional information will be provided for all parents for the study. Completed informed consent will be collected at the Department of Pediatric Dentistry, Medical University - Plovdiv by the study investigators. A copy of the signed consent form will be handed over to the participating child's parent/guardian. After providing age-appropriate information about the study, verbal assent will be obtained as an affirmative agreement for participation from children

### 5.3. Confidentiality

The information of the participants collected during the study will be kept strictly confidential and will not be disclosed to third parties. Confidentiality will be guaranteed by a coded ID number, access will be granted exclusively to the study investigators.

### 5.4. Conflict of interests

The investigators have no conflicts of interest to declare. They agree with the protocol and the informed consent of the study and there is no financial interest to report.

### 5.5. Access to data

All data collected will be stored in sealed containers in areas of the Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria with limited access. The information from the paper forms will be exported to a database file and stored on a password-protected computer. Only the investigators and statistician will have access to the final data set.

### 5.6. Dissemination policy

The results of the trial will be presented through peer-reviewed publications and conference presentations. In addition, our results will be disseminated to clinicians, as well as key stakeholders, including scientific directors of postgraduate programs "Master of Science in Lasers in Dentistry", academic courses in Pedodontics and Preventive dentistry. The principle investigator (MS) and the

### **BMJ** Open

scientific expert (AB) will write the first draft of the manuscript without the use of professional writers.

### Conclusion

The study outlined in this protocol will be the first investigated combination of the treatment effect of the Er:YAG-laser irradiation in addition to a behavior management technique. The implementation of Er:YAG-laser in the regular protocol for behavior guidance during dental treatment would significantly increase the success of this therapy resulting in lower levels of dental anxiety among pediatric dental patients.

As the literature offers no studies reporting the effectiveness of combined use of laser therapy and behavior management techniques in pediatric dentistry, there is an evident need for studies that address these outcomes, since dentists advance in using alternative methods for caries removal as part of their everyday practice.

### Trial status

The trial is not yet recruiting patients. The process will start in September 2021 and will continue untill September 2022.

### Word count: 3705

### Acknowledgements

The authors would like to show their gratitude to Assoc. Prof. Georgi Tomov, PhD for the fruitful discussion. Assistance with the Laser Center of the Faculty of Dental Medicine, Medical University of Plovdiv, Bulgaria was greatly appreciated. The authors are also thankful to Prof. Nonka Mateva, PhD for the statistical consultancy expertise in the planning of this clinical trial.

### **Author Contributions**

We declare that all authors have made substantial contributions. MS and AB conceive the ideas. AB trained MS. MS will be the primary operator, outcomes assessor, and data collector. All authors will participate in the analysis and reporting of the results. Writing will be led by MS. The design and protocol for this study were developed by AB and MS. All authors contributed to refining the study protocol and approving the final manuscript.

### Funding

This research received institutional funding from the Medical University – Plovdiv, Bulgaria.

### **Competing interests**

None declared.

### Patient consent for publication

(see Supplementary data file S1 'Patient consent form')

### References

- 1. Walsh LJ. Anxiety prevention: implementing the 4S principle in conservative dentistry. Auxilliary. 2007; 17; 24-26.
- Pagano S, Lombardo G, Orso M, Abraha I, Capobianco B, Cianetti S. Lasers to prevent dental caries: a systematic review. BMJ Open. 2020 Oct 28;10(10):e038638. doi: 10.1136/bmjopen-2020-038638.
- 3. Galui S, Pal S, Mahata S, Saha S, Sarkar S.Laser and its use in pediatric dentistry: A review of literature and a recent update. Int J Ped Reh 2019;4(1):1-5. DOI: 10.4103/ijpr.ijpr\_17\_18
- 4. American Academy of Pediatric Dentistry. Policy on the use of lasers for pediatric dental patients. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2020:116-8.
- Frencken JE, Peters MC, Manton DJ, Leal SC, Gordan VV, Eden E. Minimal intervention dentistry for managing dental caries - a review: report of a FDI task group. Int Dent J. 2012 Oct;62(5):223-43. doi: 10.1111/idj.12007.
- 6. Buldur B. Behavior Management in Pediatric Dentistry: An Overview and Interpretation.PBOCI 2019;19(1):e4649.DOI: 10.4034/PBOCI.2019.191.ed1
- Khandelwal M, Shetty RM, Rath S. Effectiveness of Distraction Techniques in Managing Pediatric Dental Patients. Int J Clin Pediatr Dent. 2019 Jan-Feb;12(1):18-24. doi: 10.5005/jpjournals-10005-1582.
- 8. Gunasekaran G,Ramakrishnan M. Evaluation of factors affecting the behaviour of uncooperative pedodontic patients. PJAEE 2020;17(7), 2027-2038. ISSN 1567-214x.

59

60

1 2	
3 9	Subramaniam P, Haqh M, Gupta M.Assessment of trait and state anxiety in 3-6-year old
4 5	children during sequential phases of dental treatment. Contemp Pediatr Dent 2020:1(1):22-32.
6 7	DOI: 10.51463/cpd.2020.10
8 1	0. Tajadura-Jimenez A, Grehl S, Tsakiris M. The other in me: Interpersonal multisensory
9 <sup>1</sup> 10	stimulation changes the mental representation of the self.PLoS ONE. 2012;7.
11 12 1	1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson
13	A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T,
14 15	Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining
16	
17 18	standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-207. doi:
19	10.7326/0003-4819-158-3-201302050-00583. PMID: 23295957; PMCID: PMC5114123.
20 21	2. Ismail AI, Sohn W, Tellez M, Amaya A, Sen A, Hasson H, Pitts NB. The International Caries
22 23	Detection and Assessment System (ICDAS): an integrated system for measuring dental caries.
23 24	Community Dent Oral Epidemiol. 2007 Jun;35(3):170-8. doi: 10.1111/j.1600-
25 26	0528.2007.00347.x.
27 1	3. International Caries Detection and Assessment System (ICDAS) Coordinating Committee.
28 29	Rationale and Evidence for the International Caries Detection and Assessment System
30	
31 32	(ICDAS II). 2011 Sept. Available from: http://www.icdas.org.
33 <sup>I</sup>	4. Pitts N. "Pitts N. "ICDAS"an international system for caries detection and assessment being
34 35	developed to facilitate caries epidemiology, research and appropriate clinical management.
36	Community Dent Health. 2004 Sep;21(3):193-8. PMID: 15470828.
37 38 1	5. Yilmaz H, Keles S. The effect of the Er: YAG laser on the clinical success of hydrophilic
39 40	fissure sealant: a randomized clinical trial. Eur Oral Res. 2020;54(3):148-153.
40	doi:10.26650/eor.20200029
42 43 1	6. Rattanacharoenthum A, Na-Lamphun P, Kantrong N. Altered adhesion of dental sealant to
44	tooth enamel microscopically modified by Er:YAG laser irradiation: An in vitro study. Laser
45 46	
47	Ther. 2019;28(1):19-25. doi:10.5978/islsm.28_19-OR-02
48 ] 49	7. LeBaron S, Zeltzer L. Assessment of acute pain and anxiety in children and adolescents by
50	self-reports, observer reports, and a behavior checklist. J Consult Clin Psychol 1984; 52:729-
51 52	38. DOI: 10.1037//0022-006x.52.5.729
53 54	
54 55	
56 57	
58	15

18. Song JS, Chung HC, Sohn S, Kim YJ. Effects of psychological behaviour management programme on dental fear and anxiety in children: A randomised controlled clinical trial. Eur J Paediatr Dent. 2020 Dec;21(4):287-291. doi: 10.23804/ejpd.2020.21.04.6.

<text>



# **Consent form**

Nai	me of patient:	
Pat	ient`s parent/guardian:	
chil	terial – text (information about your d`s oral health, level of dental riety and dynamics of heart rate):	
	visional title of article in which Material I be included:	Efficacy of Combined Er:YAG Laser Therapy and Behaviour Management Technique in Reducing Anxiety among Paediatric Dental Patients
		CONSENT
		[ENTER YOUR FULL NAME] give my consent for the
onfirm	about my child to appear in a BMJ publica that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to	ation. out my child
confirm	that I: (please tick boxes to confirm) have seen the text or other material abo	ation. out my child
onfirm	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published witho	ation. out my child
onfirm	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published witho complete anonymity cannot be gua recognise my child. The Material may show or include of	out my child BMJ but my child`s name attached, however I understand that
onfirm	that I: (please tick boxes to confirm) have seen the text or other material about the read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published with the complete anonymity cannot be guad recognise my child. The Material may show or include of prognosis, treatment or surgery that I I. The article may be published in a jour the prognoment of the prognoment of the prognoment.	ation. out my child o BMJ out my child`s name attached, however I understand that arranteed. It is possible that somebody somewhere ma details of my child's medical condition or injury and an
ndersta	that I: (please tick boxes to confirm) have seen the text or other material about the read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published with complete anonymity cannot be guar recognise my child. The Material may show or include of prognosis, treatment or surgery that I I. The article may be published in a jour mainly to doctors and other healthcar academics, students and journalists. The article, including the Material, may	ation. out my child BMJ but my child's name attached, however I understand that aranteed. It is possible that somebody somewhere mathater details of my child's medical condition or injury and an have/the patient has, had or may have in the future. Irrnal which is distributed worldwide. BMJ's publications go re professionals but are also seen by many others includin y be the subject of a press release, and may be linked to from motional activities. Once published, the article will be place
on <b>firm</b>	that I: (please tick boxes to confirm) have seen the text or other material about the submitted to am legally entitled to give this consent. and the following: The Material will be published wither complete anonymity cannot be guar recognise my child. The Material may show or include of prognosis, treatment or surgery that I I. The article may be published in a jour mainly to doctors and other healthcar academics, students and journalists. The article, including the Material, may social media and/or used in other programmed and and and and a state of the section.	ation. out my child BMJ but my child's name attached, however I understand that aranteed. It is possible that somebody somewhere mathater details of my child's medical condition or injury and an have/the patient has, had or may have in the future. Irrnal which is distributed worldwide. BMJ's publications go re professionals but are also seen by many others includin y be the subject of a press release, and may be linked to from motional activities. Once published, the article will be place



- (7) The article may also be used in full or in part in other publications and products published by BMJ and/or by other publishers. This includes publication in English and in translation, in print, in digital formats, and in any other formats that may be used by BMJ or other publishers now and in the future. The article may appear in local editions of journals or other publications, published in the UK and overseas.
- (8) I can revoke my consent at any time before publication, but once the article has been committed to publication ("gone to press") it will not be possible to revoke the consent.
- (9) This consent form will be retained securely and in confidence by BMJ in accordance with the law, for no longer than necessary. Personal data provided in this form will be used and retained in accordance with BMJ's Privacy Policy available at https://www.bmj.com/company/your-privacy/.

Signed:	Print name:
Address:	Email address:
	Telephone no:
* signing on behalf of the patient who is under the	age of 18
	Date:
Corresponding author	6
Signed:	Author`s name: Maria Shindova
Position: Senior Assistant Professor	Address: 3 Hristo Botev Bulv., Plovdiv, Bulgaria
Institution: Department of Pediatric	
Dentistry, Faculty of Dental Medicine,	
Medical University of Plovdiv	2
Email address: mariya.shindova@gmail.com	Telephone no: + 359 898 390 935
Date:	

Patient consent form 050419

## **INFORMATION LEAFLET**

### DEPARTMENT OF PAEDIATRIC DENTISTRY LASER CENTER FACULTY OF DENTAL MEDICINE, MEDICAL UNIVERSITY OF PLOVDIV, BULGARIA

### EFFICIENCY OF ER: YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS

**DESCRIPTION:** You and your child are invited to participate in a research study on the efficiency of Er:YAG laser therapy in combination with behavior management technique in reducing anxiety among pediatric dental patients.

**PROCEDURES:** With your permission, we would like to collect information about your children's dental anxiety before, during and after dental treatment of a caries lesion. This study does not involve any experiments, just preventive procedures and dental treatment, collection, and study of the required information.

**RISKS AND BENEFITS:** There are no anticipated risks associated with this study. You will not receive any direct benefit from participation.

**TIME INVOLVEMENT:** Your child's participation in this study will not require more time from you other than for the first visit including an explanation of the study, oral examination and a preventive procedure (sealant application). The second appointment at 7-day recall will include dental treatment.

**PAYMENTS:** You will not be paid to participate in this study. You will not pay for the treatment of your child in this study.

**PARTICIPANT'S RIGHTS:** If you have read this form and have decided your child to participate in this research, please understand your participation is voluntary and you have the right to withdraw your consent or discontinue participation at any time without penalty or loss of benefits to which you are otherwise entitled.

The results of this research study may be presented at scientific or professional meetings or published in scientific journals. However, your identity will not be disclosed.

Thank you for your time and attention!

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright


Name of parent/guardian
Signature of parent /guardian
Name of patient
Telephone number
Name of the dentist

Signature of the dentist

For additional information regarding the trial, you can contact us at the given address, emails, or phone numbers.

### **Researchers:**

Maria Shindova, DDS, MSc, PhD Chief Assistant Professor Department of Pediatric Dentistry Faculty of Dental Medicine Medical University – Plovdiv 3 Hristo Botev Blvd 4000 Plovdiv, Bulgaria Mobile: + 359 898 390 935 mariya.shindova@gmail.com Mariya.Shindova@mu-plovdiv.bg Ani Belcheva, DDS, MSc, PhD Professor Department of Pediatric Dentistry Faculty of Dental Medicine Medical University - Plovdiv 3 Hristo Botev Blvd 4000 Plovdiv, Bulgaria Mobile: + 359 889 528 932 abeltcheva@yahoo.com



# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

9 10 11				Page
12 13			Reporting Item	Number
14 15 16	Administrative			
17 18 19 20 21 22	information			
	Title	<u>#1</u>	Descriptive title identifying the study design, population,	1
22 23 24 25			interventions, and, if applicable, trial acronym	
26 27	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name	2
28 29			of intended registry	
30 31 32 33 34				
35 36	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	2
37 38 39 40	data set		Registration Data Set	
41 42	Protocol version	<u>#3</u>	Date and version identifier	2
43 44 45 46				
47 48 49 50	Funding	<u>#4</u>	Sources and types of financial, material, and other support	2,14
50 51 52	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	1
53 54	responsibilities:			
55 56 57 58	contributorship			
59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	2
3 4	responsibilities:			
5 6 7	sponsor contact			
7 8 9 10	information			
10 11 12	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study design;	13
13 14	responsibilities:		collection, management, analysis, and interpretation of data;	
15 16 17	sponsor and funder		writing of the report; and the decision to submit the report for	
18 19			publication, including whether they will have ultimate	
20 21			authority over any of these activities	
22 23	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
24 25	responsibilities:	<u>#00</u>	centre, steering committee, endpoint adjudication	n/a
26 27 28				
29	committees		committee, data management team, and other individuals or	
30 31 32			groups overseeing the trial, if applicable (see Item 21a for	
33 34			data monitoring committee)	
35 36	Introduction			
37 38				
39 40	Background and	<u>#6a</u>	Description of research question and justification for	3,4
41 42	rationale		undertaking the trial, including summary of relevant studies	
43 44			(published and unpublished) examining benefits and harms	
45 46			for each intervention	
47 48 49	Background and	<u>#6b</u>	Explanation for choice of comparators	3,4
50 51 52	rationale: choice of			
53 54	comparators			
55 56 57 58	Objectives	<u>#7</u>	Specific objectives or hypotheses	4
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 24 of 30

1 2 3 4 5 6 7 8 9 10	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4
10 11 12	Methods:			
13 14	Participants,			
15 16	interventions, and			
17 18 19	outcomes			
20 21 22	Study setting	<u>#9</u>	Description of study settings (eg, community clinic,	5
22 23 24			academic hospital) and list of countries where data will be	
25 26			collected. Reference to where list of study sites can be	
27 28 29 30			obtained	
30 31 32	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable,	5,6
33 34			eligibility criteria for study centres and individuals who will	
35 36 37			perform the interventions (eg, surgeons, psychotherapists)	
38 39	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to allow	5,6
40 41 42	description		replication, including how and when they will be	
42 43 44			administered	
45 46	Interventions:	#11b	Criteria for discontinuing or modifying allocated interventions	n/a
47 48 49	modifications		for a given trial participant (eg, drug dose change in	
50 51			response to harms, participant request, or improving /	
52 53			worsening disease)	
54 55 56				
56 57 58	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention protocols,	n/a
59 60		For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	adherance		and any procedures for monitoring adherence (eg, drug	
3 4			tablet return; laboratory tests)	
5 6 7 8			Non-adherence interventions in the present study	
8 9 10	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that are	n/a
11 12 13	concomitant care		permitted or prohibited during the trial	
13 14 15			No permitted or prohibited during the trial concomitant care	
16 17 18			and interventions	
19 20	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the	8,9
21 22 23			specific measurement variable (eg, systolic blood pressure),	
23 24 25			analysis metric (eg, change from baseline, final value, time	
26 27			to event), method of aggregation (eg, median, proportion),	
28 29			and time point for each outcome. Explanation of the clinical	
30 31 22			relevance of chosen efficacy and harm outcomes is strongly	
32 33 34			recommended	
35 36				
37 38	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any	9
39 40			run-ins and washouts), assessments, and visits for	
41 42			participants. A schematic diagram is highly recommended	
43 44			(see Table 1)	
45 46 47	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study	9
48 49			objectives and how it was determined, including clinical and	
50 51			statistical assumptions supporting any sample size	
52 53 54			calculations	
55 56 57 58	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to	9
59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			reach target sample size	
3 4 5 6 7	Methods:			
	Assignment of			
, 8 9	interventions (for			
10 11	controlled trials)			
12 13 14	Allocation: sequence	<u>#16a</u>	Method of generating the allocation sequence (eg,	10
15 16	generation		computer-generated random numbers), and list of any	
17 18 19			factors for stratification. To reduce predictability of a random	
20 21			sequence, details of any planned restriction (eg, blocking)	
22 23			should be provided in a separate document that is	
24 25 26			unavailable to those who enrol participants or assign	
27 28			interventions	
29 30 31	Allocation	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg,	10
32 33	concealment		central telephone; sequentially numbered, opaque, sealed	
34 35	mechanism		envelopes), describing any steps to conceal the sequence	
36 37 38			until interventions are assigned	
39 40	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will enrol	10
41 42 43	implementation		participants, and who will assign participants to interventions	
44 45	Plinding (macking)	#170	Whe will be blinded ofter accimpant to interventions (or	10
46 47	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg,	10
48 49 50			trial participants, care providers, outcome assessors, data	
51 52			analysts), and how	
53 54	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	n/a
55 56	emergency		permissible, and procedure for revealing a participant's	
57 58 59	unblinding		allocated intervention during the trial	
60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3			open-label trial	
4 5	Methods: Data			
6 7	collection,			
8 9 10	management, and			
11 12	analysis			
13 14 15 16	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline,	10
17 18			and other trial data, including any related processes to	
19 20			promote data quality (eg, duplicate measurements, training	
21 22			of assessors) and a description of study instruments (eg,	
23 24			questionnaires, laboratory tests) along with their reliability	
25 26			and validity, if known. Reference to where data collection	
27 28 29 30			forms can be found, if not in the protocol	
31 32	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete follow-	10,11
33 34	retention		up, including list of any outcome data to be collected for	
35 36			participants who discontinue or deviate from intervention	
37 38 39			protocols	
40 41 42	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including	10,11
42 43 44			any related processes to promote data quality (eg, double	
45 46			data entry; range checks for data values). Reference to	
47 48			where details of data management procedures can be	
49 50 51			found, if not in the protocol	
52 53 54	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary	11
55 56			outcomes. Reference to where other details of the statistical	
57 58			analysis plan can be found, if not in the protocol	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and	11
3 4 5	analyses		adjusted analyses)	
6 7 8	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol non-	11
9 10	population and		adherence (eg, as randomised analysis), and any statistical	
11 12 13	missing data		methods to handle missing data (eg, multiple imputation)	
14 15 16	Methods: Monitoring			
17 18	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC); summary	12
19 20	formal committee		of its role and reporting structure; statement of whether it is	
21 22 23			independent from the sponsor and competing interests; and	
23 24 25			reference to where further details about its charter can be	
26 27			found, if not in the protocol. Alternatively, an explanation of	
28 29 30			why a DMC is not needed	
31 32 33	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping guidelines,	n/a
34 35	interim analysis		including who will have access to these interim results and	
36 37 38			make the final decision to terminate the trial	
39 40	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing	n/a
41 42			solicited and spontaneously reported adverse events and	
43 44 45			other unintended effects of trial interventions or trial conduct	
46 47 48	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any,	n/a
49 50			and whether the process will be independent from	
51 52 53			investigators and the sponsor	
54 55	Ethics and			
56 57 58	dissemination			
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Research ethics	<u>#24</u>	Plans for seeking research ethics committee / institutional	11,12
3 4 5 6 7 8 9 10	approval		review board (REC / IRB) approval	
	Protocol	<u>#25</u>	Plans for communicating important protocol modifications	11,12
	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
11 12			relevant parties (eg, investigators, REC / IRBs, trial	
13 14 15			participants, trial registries, journals, regulators)	
16 17	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential	12
18 19 20			trial participants or authorised surrogates, and how (see	
20 21 22			Item 32)	
23 24 25	Consent or assent:	<u>#26b</u>	Additional consent provisions for collection and use of	n/a
26 27	ancillary studies		participant data and biological specimens in ancillary	
28 29 30			studies, if applicable	
31 32	Confidentiality	<u>#27</u>	How personal information about potential and enrolled	12
33 34 35			participants will be collected, shared, and maintained in	
36 37			order to protect confidentiality before, during, and after the	
38 39 40			trial	
40 41 42	Declaration of	<u>#28</u>	Financial and other competing interests for principal	12
43 44	interests		investigators for the overall trial and each study site	
45 46 47	Data access	#29	Statement of who will have access to the final trial dataset.	12
48 49		<u></u>	and disclosure of contractual agreements that limit such	
50 51 52			access for investigators	
53 54		#00		
55 56	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for	n/a
57 58 59	trial care		compensation to those who suffer harm from trial	
60	I	For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			participation	
3 4	Dissemination	<u>#31a</u>	Plans for investigators and sponsor to communicate trial	12,13
5 6 7	policy: trial results		results to participants, healthcare professionals, the public,	
8 9			and other relevant groups (eg, via publication, reporting in	
10 11			results databases, or other data sharing arrangements),	
12 13 14			including any publication restrictions	
15 16 17	Dissemination	<u>#31b</u>	Authorship eligibility guidelines and any intended use of	12
18 19	policy: authorship		professional writers	
20 21	Dissemination	<u>#31c</u>	Plans, if any, for granting public access to the full protocol,	n/a
22 23 24	policy: reproducible		participant-level dataset, and statistical code	
25 26	research			
27 28 29 30	Appendices			
31 32 33	Informed consent	<u>#32</u>	Model consent form and other related documentation given	Suppl 1-
34 35	materials		to participants and authorised surrogates	3
36 37 38 39				
40 41	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of	n/a
42 43 44			biological specimens for genetic or molecular analysis in the	
44 45 46			current trial and for future use in ancillary studies, if	
47 48			applicable	
49 50				
51 52 53				
54 55				
56 57				
58 59	E		aview only http://bmienen.hmi.com/site/about/guidelines.yhtml	

# **BMJ Open**

### EFFICIENCY OF ER:YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS: A STUDY PROTOCOL FOR A RANDOMIZED CLINICAL TRIAL

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-054523.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Dec-2021
Complete List of Authors:	Belcheva, Ani; Medicinski universitet-Plovdiv, Department of Paediatric Dentistry Shindova, Maria; Medicinski universitet-Plovdiv, Department of Paediatric Dentistry
<b>Primary Subject Heading</b> :	Dentistry and oral medicine
Secondary Subject Heading:	Dentistry and oral medicine
Keywords:	Paediatric anaesthesia < ANAESTHETICS, Laser therapy < DERMATOLOGY, Child & adolescent psychiatry < PSYCHIATRY, Anxiety disorders < PSYCHIATRY



# EFFICIENCY OF ER:YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS: A STUDY PROTOCOL FOR A RANDOMIZED CLINICAL TRIAL

### <sup>1</sup>Ani Bozhidarova Belcheva, <sup>2</sup>Maria Petrova Shindova

<sup>1</sup> DDS, PhD, MSc, Professor, Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, abeltcheva@yahoo.com, vice\_rector\_ea@mu-plovdiv.bg, ORCID iD: 0000-0002-9625-8684

<sup>2</sup> DDS, PhD, Senior Assistant Professor, Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, mariya.shindova@gmail.com, Mariya.Shindova@mu-plovdiv.bg, ORCID iD: 0000-0003-2996-3700

### **Corresponding author**

Maria Shindova, DDS, MSc, PhD Senior Assistant Professor Department of Paediatric Dentistry Faculty of Dental Medicine Medical University - Plovdiv 3 Hristo Botev Blvd 4000 Plovdiv, Bulgaria Mobile: + 359 898 390 935 email: mariya.shindova@gmail.com Mariya.Shindova@mu-plovdiv.bg

### Abstract

### Introduction

When providing dental care to children with a high level of dental anxiety, the range of approaches are divided into two sections – use of behavior management techniques and application of alternative methods for caries removal. In an attempt to reduce dental anxiety, they can be mixed and matched in accordance with the dentists' choice. Owing to the promoted advantages Er:YAG laser turns into an ideal alternative technique for hard dental tissue therapy in anxious pediatric

patients. The aim of the study is to assess the efficacy of a modified version of the behavior management technique Latent inhibition in combination with Er:YAG laser for achieving a reduction of dental anxiety in pediatric dental patients.

### Methods and analysis

This is a protocol for a randomized controlled clinical trial. The participants will be children aged 6-9 years, requiring conservative treatment of occlusal carious lesion on a second primary molar. Patients will be randomly assigned to the experimental or control group via a computer-generated sequence. In both groups, Latent inhibition will be used as an anxiety-management technique. In the experimental group caries treatment will be performed with Erbium:YAG laser, whereas in the control group with the conventional rotary instruments. Outcome measures will be dental anxiety felt before and after the treatment, reported by the patient on a modified version of Faces Scale by LeBaron and the dynamics of heart rate, registered during the treatment session, measured with a mobile pulse oximeter. Data will be analyzed by Independent sample t-test and paired t-test, p<0.05.

### Ethics and dissemination

The study protocol has been approved by the Committee for Scientific Research Ethics, Medical University-Plovdiv, Bulgaria (Reference number P-2839, Protocol of approval No. 3/30.04.2015) and registered on a publicly accessible database. This research received institutional funding from the Medical University–Plovdiv, Bulgaria. The results will be presented through peer-reviewed publications and conference presentations.

Trial registration: ClinicalTrials.gov (Registration number: NCT04924452).

Keywords: Er: YAG laser, anxiety, management technique, pediatric dentistry

### Article Summary

### Strengths and limitations of this study

• The study focuses on the implementation of a known behavior management technique in the alternative caries treatment method resulting in a reduction of dental anxiety in pediatric dental patients.

- This is the first trial to study the efficacy of Er:YAG laser therapy in combination with a behavior management technique in reducing anxiety among pediatric dental patients.
- A key strength of this study is that all participants meeting eligibility criteria will receive active treatment.
- Both subjective and objective tools are used to assess dental anxiety in this study.
- A limitation of this study is that it is not a split-mouth design whose advantage is the reduction of the outcome variability estimation, leading to the potential increase in statistical power.
- 1. Introduction
- 1.1. Background and rationale

When providing dental care to children with a high level of dental anxiety, most pediatric dentists find the conventional rotary treatment method inefficient and uncomfortable. According to the principles of behavioral dentistry, as part of pediatric postgraduate education, the so-called `4S` principle must be adapted and modified to the individual clinical situation to provide adequate dental care to anxious pediatric patients <sup>1</sup>. The range of approaches can be divided into two sections – behavior management techniques (BMTs), on one hand, and alternative methods for caries removal, on the other hand. In an attempt to reduce dental anxiety, they can be mixed and matched in accordance with the dentists' choice.

As it has been found for more than 20 years that lasers are effective for caries excavation, Laser pediatric dentistry has been rapidly developed. It offers total innovation and changes the conventional restorative treatment in pedodontics <sup>2</sup>. Owing to the promoted advantages such as minimal intervention and prevention, safety due to the low penetration depth of the laser beam, selective removal of caries lesion, lack of thermal damage, no pain perception and use of local anesthesia, a significant decrease of patient discomfort and dental anxiety and increase of subjective acceptance and tolerance of laser therapy in children, Er:YAG laser turns into an ideal laser for hard dental tissue therapy in anxious pediatric patients <sup>2</sup>,3,4.

Based on the concepts of Minimal Invasive Dentistry (MID), the use of BMTs during the treatment of anxious children to reduce their anxiety is required <sup>5</sup>. Several specific BMTs are not part of the regular curricula of dental students and have been used by pediatric dentists only<sup>4,6,7</sup>. Such a phycological technique is Latent inhibition also known as Gradual exposure <sup>8,9</sup>. It involves a series of several positive non-painful – check-ups and preventive procedures, before any invasive or

painful dental manipulations. Step by step the child is exposed to potential anxiety-provoking procedures or instruments, resulting in an acquaintance with the dental setting and personnel, as well as being accustomed to dental treatment. Despite the specific indications, required preparation and higher time consumption, the use of this technique is very rewarding as the pediatric patient eventually becomes comfortable with the dental procedure and creates a feeling of ability to cope within the child <sup>6,7,10</sup>.

Over the recent years, dentists advance in using alternative methods for caries removal as part of their everyday practice. Therefore, the investigation of this synergetic effect of laser caries removal and the different BMTs is crucial for the present and future development of pediatric dentistry and will improve the quality of dental care.

1.2. Objectives

The aim of the study is to assess the efficacy of a modified version of the BMT Latent inhibition in combination with Er:YAG laser for achieving a reduction of dental anxiety in paediatric dental patients. The main objectives are to compare dental anxiety felt during the laser and conventional dental treatment. The outcomes will be dental anxiety assessment by self-reported anxiety scale during treatment in both groups as well as the measurement of heart rate dynamics during the procedures.

1.3. Trial design

The research is designed as a randomized parallel-group controlled clinical study. Table 1 presents the recruiting, allocation, interventions, monitoring, and analysis of the research in accordance with the Standard Protocol Items: Recommendations for Interventional Trials recommendations<sup>11</sup>. In accordance with the Latent inhibition technique patients will have two visits to the dental office – a preventive procedure, the first one, and treatment of caries lesion, the second one. Two groups will be compared. In the experimental group the enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment will be performed with Erbium:YAG laser, whereas in the control group the conventional rotary instruments - high-speed and low-speed dental handpieces, will be used for the caries treatment.

		STUDY PER	RIOD			
	Enrolment	Allocation	Pos	t-alloca	tion	
TIMEPOINT*	-t <sub>1</sub>	0	t <sub>1</sub>	$t_1$ $t_2$		
ENROLMENT						
Eligibility screening	×					
Informed consent	×					
Allocation		×				
INTERVENTIONS						
Experimental group				×		
(BMT + Laser treatment of dental caries)						
Control group	4					
(BMT + Caries treatment with	0.			×		
conventional rotary instruments)	14.					
ASSESSMENTS	0					
Self-reported dental anxiety	1	1	×		×	
Heart rate			-		-	

Table 1. Trial design. The table summarises the enrolment, allocation, interventions, and assessments in the trail

\*Post-allocation time frame: t1 - before the start of the treatment;  $t_2$  - during laser or conventional treatment;  $t_3$  - end of the treatment, before leaving the dental chair.

- 2. Methods and analyses
- 2.1. Study setting

The study setting of this research includes the Department of Paediatric Dentistry and the Laser Centre of the Faculty of Dental medicine, Medical University – Plovdiv, Bulgaria.

- 2.2. Eligibility
- 2.2.1. Inclusion criteria

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright

- 1. Participants in the study are children aged 6-9 years, compliant with the cognitive development of the child;
- 2. Children, requiring conservative treatment of occlusal carious lesions on a second primary molar, without spontaneous unprovoked pain, percussion or palpation pain or other symptoms, indicating pulp involvement or periodontal pathology. Lesions are classified as a distinct cavity with visible dentin without prior restoration or sealants by the International Caries Detection and Assessment System (ICDAS) with code 05 <sup>12,13,14</sup>. Included are caries lesions only on vital teeth.
- 3. Children with one or more permanent molars giving indications for pit and fissure sealing;
- 4. Patients without previous experience with laser treatment of carious lesions;
- 5. Children who are not considered medically compromised or medically complex patients;
- 6. Verbal assent from the child willing to comply with all study procedures and protocol;
- 7. Obtained written informed consent by the patient's parent/guardian for participation in the study (see supplementary data file S1 'Patient consent form' and S2 'Information leaflet').
- 2.2.2. Exclusion criteria

- 1. Patients who were undergoing therapy with neurological, sedative, analgesic, and/or antiinflammatory drugs 7 days prior to treatment that might affect heart rate;
- 2. Children, who were first-time dental patients;
- 3. Children with systemic diseases or physiological development delays;
- 4. Children with mental or cognitive problems;
- 5. Active infectious diseases such as influenza, scarlet fever, etc.
- 6. Excluded are molars which are affected by disturbances in the development of dental structures (hypoplasia, hypomineralization, fluorosis)
- 2.2.3. Interventions

Patients will be divided into 2 groups (41 per group) – experimental and control groups. All treatments will be carried out by the same operator (MS), without anesthesia. A baseline dental self-reported anxiety will be recorded using a Faces anxiety scale as well as the dynamics of heart rate, measured with a mobile pulse oximeter.

## Er: YAG laser therapy protocol (experimental group):

### **BMJ** Open

Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment. Chosen protocol parameters are modified based on previously conducted studies <sup>2,3,4,15,16</sup>:

- preventive procedure sealant application:
- a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar;

- tooth surface will be washed for debris and organic residue removal and dried with air spray;

- isolation with rubber dam;
- laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 μm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm<sup>2</sup>;
- tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time;
- tooth surface will be dried with air spray for 15s;
- fissure sealant application (Pit&Fisssure Sealant, DMP Ltd);
- light cured for 20 seconds.

caries removal – parameters: enamel removal – energy 100-200mJ; density 9.84-13.03 J/cm<sup>2</sup>, pulse frequency 20Hz; tip diameter 800  $\mu$ m; water spray level 8; tip-to-tissue distance 0.5÷1 mm from the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm<sup>2</sup>, pulse frequency 20Hz; tip diameter 800  $\mu$ m; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer. Time for caries removal procedure – max 8 minutes <sup>17,18,19,20</sup>.

## Conventional therapy protocol (control group):

- preventive procedure sealant application
- a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar;
- tooth surface will be washed for debris and organic residue removal and dried with air spray;
- isolation with rubber dam;

- tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time;
- tooth surface will be dried with air spray for 15s;
- fissure sealant application (Pit&Fisssure Sealant, DMP Ltd);
- light cured for 20 seconds.

• caries removal – conventional rotary instruments will be used - high-speed and low-speed dental handpieces. For the bur preparation 1.2 mm diameter diamond round bur Drendel & Zweiling No. 801.314. and Komet Steel round bur 016, Komet Dental Gebr were used. A new bur was used for each preparation. Restoration with compomer. Time for caries removal procedure – max 4 minutes.

2.2.4. Clinical protocol

First visit:

- 1. Parents/guardians are informed about the protocol of the study and the laser technique. They sign the informed consent form (see Supplementary data files S1 and S2). Verbal assent from the child is obtained.
- 2. Oral examination and sealant application are performed according to the assigned intervention.
- 3. Patient's self-report of dental anxiety before leaving the dental chair.

Second visit:

- Patients will be asked to report their dental anxiety, pointing to the face or choose the number which most closely depicted its state of anxiety using a modified version of the self-report Faces Scale by LeBaron et al.<sup>21</sup> (see Supplementary data file S3)
- 2. Pulse-oximeter is connected to the patient's index finger. The start of heart rate monitoring and recording will be 5 minutes prior to treatment. Time frame: at least 5 minutes after the dental treatment, before leaving the dental chair.
  - 3. Caries treatment is performed according to the assigned intervention.
  - 4. Patient's self-report of dental anxiety before leaving the dental chair.
- 2.3. Outcomes
- 2.3.1. Primary outcome measures

The primary outcome will be the dental anxiety before and after the treatment session, reported by the patient on a modified version of the self-report Faces Scale by LeBaron et al.. The scale

#### **BMJ** Open

comprises a row of five faces ranging from `relaxed` to `very worried` in combination with a visual analog scale of 0 - 10. Each child was asked to point to the face or choose the number which most closely depicted its state of anxiety.

2.3.2. Secondary outcome measures

The secondary outcome will be the dynamics of heart rate, registered during the treatment session measured with a mobile pulse oximeter (CMS50F, CONTEC), placed on the index finger of the left hand <sup>22</sup>. Throughout the whole procedure of each dental visit, data were recorded and analyzed by a specially developed digital processing and graphic visualization software SPO2 Review V1.2 rel.

2.3.3. Participant's timeline

Each eligible patient undergoes two visits. The first appointment includes screening, consenting and assenting, recording of dental anxiety, sealant application according to the assigned interventions for each group. The second appointment at the one-week recall includes a recording of dental anxiety and treatment of a carious lesion according to the assigned interventions for each group. The manipulations will be performed by one operator.

2.3.4. Sample size calculation

The sample size calculation is performed based on data from a pilot study with 20 subjects. To estimate sample size for the primary outcome—self-reported anxiety felt, according to the Faces Scale by LeBaron —a t-test for paired groups has been used (G\* Power software V.3.1,6 since we have two groups). The effect size was determined using the formula

$$ES = \frac{Control - Treated}{SDpooled} = \frac{2.33 - 0.33}{3.25} = 0.62$$

where SD is the pooled SD, an average of the SD of the experimental and control groups. The sample size is calculated to assure a test power greater than 95% and a significant level of  $\alpha = 0.05$ . We estimated a sample size of 41 patients per group to detect significant differences. Thus, the final sample size for this study will be 82 patients.

## 2.4. Recruitment

The patients at the Department of Paediatric Dentistry of the Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, who meet the inclusion criteria, will be screened for eligibility.

Once identified, patients will be informed about this research project and will receive information about the possibility of potential study participation. Patient recruitment starts obtaining the full quota of participants within a one-year time frame. It begins in September 2021 with an estimated enrollment capacity of 5 patients per month.

2.5. Participating centers

The patients are randomly selected from the visitors in the Department of Paediatric Dentistry of the Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, and treated in the Laser Centre of the same university.

2.6. Assignment of the intervention

2.6.1. Sequence generation

The patients will be randomly allocated to either the control group or the experimental group (41 patients in each group) according to the enrolment number in the trial. The randomization will be created using a computerized random generator.

2.6.2. Allocation concealment mechanism and implementation

A randomization list will be created by a random generator before the start of the treatment and kept in a locked drawer. Assignments will be kept in separate, closed opaque, sequentially numbered envelopes, enabling the sequence to be concealed until the intervention is assigned.

2.6.3. Blinding

The randomisation will be independent, that is, the patients and parents/guardians will remain blinded to group status. The operator will get acquainted with the procedure to be performed prior to the first session. The operator is selected to be the only one performing the manipulation to prevent bias. The statistician will be blinded to treatment assignment as data will be masked before the analysis without giving the statistician the key.

2.6.4. Data collection, confidentiality, storage, and monitoring of the study documents

Collection, coding, storage, and evaluation of personal data within the project will be carried out in accordance with The General Data Protection Regulation (EU) 2016/679 (*GDPR*). A prerequisite for data collection will be the voluntary written informed consent of the patient's

## **BMJ** Open

parent or guardian. Confidentiality will be guaranteed by a coded ID number, access will be granted exclusively to the study investigators. The information from the paper forms will be exported to a database file and stored on a password-protected computer. Only the investigators and statistician will have access to the final data set. All data collected will be stored in sealed containers in areas of the Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria with limited access.

3. Statistical methods

The obtained data will be recorded, tabulated, processed, and analyzed using SPSS (Statistical Package for Social Science software) version 21.0 (IBM, USA). In all tests, the significance level of 5% probability or the corresponding *P*-value will be adopted. Descriptive statistics will be calculated. Discrete variables will be summarised by frequencies or proportions. Continuous variables will be presented as means and standard deviations. We will compare anxiety mean scores according to the Faces Scale by LeBaron as well as heart rate mean score. Comparisons among groups will be performed by using the Independent sample t-test and paired t-test.

4. Patient and public involvement

The development of the research question and outcome measures will be based on the review of available evidence in this research area. Patients will not be involved in the development of the study protocol. However, their questions and concerns will be addressed during patient recruitment and study implementation. During the conduction of the study, patients will not be informed about the results of the ongoing trial since there is no planned interim analysis. The results will be disseminated to the study participants through email and routine follow-up dental check-ups.

5. Ethics and dissemination

The clinical study will be conducted in accordance with the conditions and principles of the Declaration of Helsinki, the existing EU Clinical Trial Directive (EC) No. 2001/20/EC, the recommendations of the Ethical Committee at the Medical University of Plovdiv, Bulgaria and the international ethical and scientific quality standard for designing, recording and reporting trials that involve the participation of human subjects - Good Clinical Practices (GCP).

5.1. Research ethics approval

The study was approved by the Committee for Scientific Research Ethics, Medical University -Plovdiv, Bulgaria (Reference number P-2839, Protocol of approval No.3/30.04.2015) and registered on a publicly accessible database ClinicalTrials.gov (Registration number: NCT04924452). Ethical approval for the study protocol and the written informed consent for all subjects' parents/guardians was granted by the Ethics Committee of the Medical University, Plovdiv, Bulgaria.

### 5.2. Consent

The operators will obtain written consent from patients' parents/guardians willing to participate in the trial. Additional information will be provided for all parents for the study. Completed informed consent will be collected at the Department of Pediatric Dentistry, Medical University - Plovdiv by the study investigators. A copy of the signed consent form will be handed over to the participating child's parent/guardian. After providing age-appropriate information about the study, verbal assent will be obtained as an affirmative agreement for participation from children

## 5.3. Confidentiality

The information of the participants collected during the study will be kept strictly confidential and will not be disclosed to third parties. Confidentiality will be guaranteed by a coded ID number, access will be granted exclusively to the study investigators.

## 5.4. Conflict of interests

The investigators have no conflicts of interest to declare. They agree with the protocol and the informed consent of the study and there is no financial interest to report.

## 5.5. Access to data

All data collected will be stored in sealed containers in areas of the Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria with limited access. The information from the paper forms will be exported to a database file and stored on a password-protected computer. Only the investigators and statistician will have access to the final data set.

## 5.6. Dissemination policy

The results of the trial will be presented through peer-reviewed publications and conference presentations. In addition, our results will be disseminated to clinicians, as well as key stakeholders, including scientific directors of postgraduate programs "Master of Science in Lasers in Dentistry", academic courses in Pedodontics and Preventive dentistry. The principle investigator (MS) and the scientific expert (AB) will write the first draft of the manuscript without the use of professional writers.

## Conclusion

The study outlined in this protocol will be the first investigated combination of the treatment effect of the Er:YAG-laser irradiation in addition to a behavior management technique. The implementation of Er:YAG-laser in the regular protocol for behavior guidance during dental treatment would significantly increase the success of this therapy resulting in lower levels of dental anxiety among pediatric dental patients.

As the literature offers no studies reporting the effectiveness of combined use of laser therapy and behavior management techniques in pediatric dentistry, there is an evident need for studies that address these outcomes, since dentists advance in using alternative methods for caries removal as part of their everyday practice.

## Trial status

The trial is not yet recruiting patients. The process will start in September 2021 and will continue until September 2022.

## Word count: 3705

### Acknowledgements

The authors would like to show their gratitude to Assoc. Prof. Georgi Tomov, PhD for the fruitful discussion. Assistance with the Laser Center of the Faculty of Dental Medicine, Medical University of Plovdiv, Bulgaria was greatly appreciated. The authors are also thankful to Prof. Nonka Mateva, PhD for the statistical consultancy expertise in the planning of this clinical trial.

## **Author Contributions**

We declare that all authors have made substantial contributions. MS and AB conceive the ideas. AB trained MS. MS will be the primary operator, outcomes assessor, and data collector. All authors will participate in the analysis and reporting of the results. Writing will be led by MS. The design and protocol for this study were developed by AB and MS. All authors contributed to refining the study protocol and approving the final manuscript.

## Funding

This research received institutional funding from the Medical University – Plovdiv, Bulgaria.

## **Competing interests**

None declared.

## Patient consent for publication

(see Supplementary data file S1 'Patient consent form')

## References

- Walsh LJ. Anxiety prevention: implementing the 4S principle in conservative dentistry. Auxilliary. 2007; 17; 24-26.
- Pagano S, Lombardo G, Orso M, Abraha I, Capobianco B, Cianetti S. Lasers to prevent dental caries: a systematic review. BMJ Open. 2020 Oct 28;10(10):e038638. doi: 10.1136/bmjopen-2020-038638.
- 3. Galui S, Pal S, Mahata S, Saha S, Sarkar S.Laser and its use in pediatric dentistry: A review of literature and a recent update. Int J Ped Reh 2019;4(1):1-5. DOI: 10.4103/ijpr.ijpr\_17\_18
- American Academy of Pediatric Dentistry. Policy on the use of lasers for pediatric dental patients. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2020:116-8.
- Frencken JE, Peters MC, Manton DJ, Leal SC, Gordan VV, Eden E. Minimal intervention dentistry for managing dental caries - a review: report of a FDI task group. Int Dent J. 2012 Oct;62(5):223-43. doi: 10.1111/idj.12007.
- 6. Buldur B. Behavior Management in Pediatric Dentistry: An Overview and Interpretation.PBOCI 2019;19(1):e4649.DOI: 10.4034/PBOCI.2019.191.ed1

7.	Khandelwal M, Shetty RM, Rath S. Effectiveness of Distraction Techniques in Managing
	Pediatric Dental Patients. Int J Clin Pediatr Dent. 2019 Jan-Feb;12(1):18-24. doi: 10.5005/jp journals-10005-1582.
8.	Gunasekaran G,Ramakrishnan M. Evaluation of factors affecting the behaviour of
	uncooperative pedodontic patients. PJAEE 2020;17(7), 2027-2038. ISSN 1567-214x.
9.	Subramaniam P, Haqh M, Gupta M.Assessment of trait and state anxiety in 3-6-year old
	children during sequential phases of dental treatment. Contemp Pediatr Dent 2020:1(1):22-32 DOI: 10.51463/cpd.2020.10
10.	Tajadura-Jimenez A, Grehl S, Tsakiris M. The other in me: Interpersonal multisensory
	stimulation changes the mental representation of the self.PLoS ONE. 2012;7.
11.	Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson
	A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T
	Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining
	standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-207. doi:
	10.7326/0003-4819-158-3-201302050-00583. PMID: 23295957; PMCID: PMC5114123.
12.	Ismail AI, Sohn W, Tellez M, Amaya A, Sen A, Hasson H, Pitts NB. The International Caries
	Detection and Assessment System (ICDAS): an integrated system for measuring dental caries
	Community Dent Oral Epidemiol. 2007 Jun;35(3):170-8. doi: 10.1111/j.1600-
	0528.2007.00347.x.
3.	International Caries Detection and Assessment System (ICDAS) Coordinating Committee.
	Rationale and Evidence for the International Caries Detection and Assessment System
	(ICDAS II). 2011 Sept. Available from: http://www.icdas.org.
14.	Pitts N. "Pitts N. "ICDAS"an international system for caries detection and assessment being
	developed to facilitate caries epidemiology, research and appropriate clinical management
	Community Dent Health. 2004 Sep;21(3):193-8. PMID: 15470828.
15.	Yilmaz H, Keles S. The effect of the Er: YAG laser on the clinical success of hydrophilic
	fissure sealant: a randomized clinical trial. Eur Oral Res. 2020;54(3):148-153
	doi:10.26650/eor.20200029
16.	Rattanacharoenthum A, Na-Lamphun P, Kantrong N. Altered adhesion of dental sealant to
	tooth enamel microscopically modified by Er:YAG laser irradiation: An in vitro study. Laser
	Ther. 2019;28(1):19-25. doi:10.5978/islsm.28_19-OR-02
	15
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 Sarmadi R, Andersson EV, Lingström P, Gabre P. A Randomized Controlled Trial Comparing Er:YAG Laser and Rotary Bur in the Excavation of Caries - Patients' Experiences and the Quality of Composite Restoration. Open Dent J 2018;12:443-454. doi:10.2174/1874210601812010443.

- Li T, Zhang X, Shi H, Ma Z, Lv B, Xie M. Er:YAG laser application in caries removal and cavity preparation in children: a meta-analysis. Lasers Med Sci 2018. doi:10.1007/s10103-018-2582-x
- 19. Johar S, Goswami M, Kumar G, Dhillon JK. Caries removal by Er,Cr:YSGG laser and Airrotor handpiece comparison in primary teeth treatment: an *in vivo* study. Laser Ther. 2019;28(2):116-122. doi:10.5978/islsm.19-OR-08.
- Montedori A, Abraha I, Orso M, D'Errico PG, Pagano S, Lombardo G. Lasers for caries removal in deciduous and permanent teeth. Cochrane Database Syst Rev 2016;9(9):CD010229. doi:10.1002/14651858.CD010229.pub2
- 21. LeBaron S, Zeltzer L. Assessment of acute pain and anxiety in children and adolescents by self-reports, observer reports, and a behavior checklist. J Consult Clin Psychol 1984; 52:729-38. DOI: 10.1037//0022-006x.52.5.729
- 22. Song JS, Chung HC, Sohn S, Kim YJ. Effects of psychological behaviour management programme on dental fear and anxiety in children: A randomised controlled clinical trial. Eur J Paediatr Dent. 2020 Dec;21(4):287-291. doi: 10.23804/ejpd.2020.21.04.6.



## **Consent form**

Nai	me of patient:	
Pat	ient`s parent/guardian:	
chil	terial – text (information about your d`s oral health, level of dental riety and dynamics of heart rate):	
Provisional title of article in which Materia will be included:		Efficacy of Combined Er:YAG Laser Therapy and Behaviour Management Technique in Reducing Anxiety among Paediatric Dental Patients
		CONSENT
		[ENTER YOUR FULL NAME] give my consent for the
onfirm	about my child to appear in a BMJ publica that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to	ation. out my child
confirm	that I: (please tick boxes to confirm) have seen the text or other material abo	ation. out my child
onfirm	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published witho	ation. out my child
onfirm	that I: (please tick boxes to confirm) have seen the text or other material about the read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published with complete anonymity cannot be guar recognise my child. The Material may show or include of the following include of the follo	out my child BMJ but my child`s name attached, however I understand that
onfirm	that I: (please tick boxes to confirm) have seen the text or other material about the read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published with the complete anonymity cannot be guad recognise my child. The Material may show or include of prognosis, treatment or surgery that I I. The article may be published in a jour the prognoment of the prognoment of the prognoment.	ation. out my child o BMJ out my child`s name attached, however I understand that arranteed. It is possible that somebody somewhere ma details of my child's medical condition or injury and an
ndersta	that I: (please tick boxes to confirm) have seen the text or other material about the read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published with complete anonymity cannot be guar recognise my child. The Material may show or include of prognosis, treatment or surgery that I I. The article may be published in a jour mainly to doctors and other healthcar academics, students and journalists. The article, including the Material, may	ation. out my child BMJ but my child's name attached, however I understand that aranteed. It is possible that somebody somewhere many details of my child's medical condition or injury and any have/the patient has, had or may have in the future. Irrnal which is distributed worldwide. BMJ's publications go re professionals but are also seen by many others including y be the subject of a press release, and may be linked to from motional activities. Once published, the article will be place
on <b>firm</b>	that I: (please tick boxes to confirm) have seen the text or other material about the submitted to am legally entitled to give this consent. and the following: The Material will be published wither complete anonymity cannot be guar recognise my child. The Material may show or include of prognosis, treatment or surgery that I I. The article may be published in a jour mainly to doctors and other healthcar academics, students and journalists. The article, including the Material, may social media and/or used in other programmed and and and and a state of the state of	ation. out my child BMJ but my child's name attached, however I understand that aranteed. It is possible that somebody somewhere many details of my child's medical condition or injury and any have/the patient has, had or may have in the future. Irrnal which is distributed worldwide. BMJ's publications go re professionals but are also seen by many others including y be the subject of a press release, and may be linked to from motional activities. Once published, the article will be place



- (7) The article may also be used in full or in part in other publications and products published by BMJ and/or by other publishers. This includes publication in English and in translation, in print, in digital formats, and in any other formats that may be used by BMJ or other publishers now and in the future. The article may appear in local editions of journals or other publications, published in the UK and overseas.
- (8) I can revoke my consent at any time before publication, but once the article has been committed to publication ("gone to press") it will not be possible to revoke the consent.
- (9) This consent form will be retained securely and in confidence by BMJ in accordance with the law, for no longer than necessary. Personal data provided in this form will be used and retained in accordance with BMJ's Privacy Policy available at https://www.bmj.com/company/your-privacy/.

Signed:	Print name:
Address:	Email address:
	Telephone no:
* signing on behalf of the patient who is under the	age of 18
	Date:
Corresponding author	6
Signed:	Author`s name: Maria Shindova
Position: Senior Assistant Professor	Address: 3 Hristo Botev Bulv., Plovdiv, Bulgaria
Institution: Department of Pediatric	
Dentistry, Faculty of Dental Medicine,	
Medical University of Plovdiv	2
Email address: mariya.shindova@gmail.com	Telephone no: + 359 898 390 935
Date:	

Patient consent form 050419

## **INFORMATION LEAFLET**

## DEPARTMENT OF PAEDIATRIC DENTISTRY LASER CENTER FACULTY OF DENTAL MEDICINE, MEDICAL UNIVERSITY OF PLOVDIV, BULGARIA

## EFFICIENCY OF ER: YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS

**DESCRIPTION:** You and your child are invited to participate in a research study on the efficiency of Er:YAG laser therapy in combination with behavior management technique in reducing anxiety among pediatric dental patients.

**PROCEDURES:** With your permission, we would like to collect information about your children's dental anxiety before, during and after dental treatment of a caries lesion. This study does not involve any experiments, just preventive procedures and dental treatment, collection, and study of the required information.

**RISKS AND BENEFITS:** There are no anticipated risks associated with this study. You will not receive any direct benefit from participation.

**TIME INVOLVEMENT:** Your child's participation in this study will not require more time from you other than for the first visit including an explanation of the study, oral examination and a preventive procedure (sealant application). The second appointment at 7-day recall will include dental treatment.

**PAYMENTS:** You will not be paid to participate in this study. You will not pay for the treatment of your child in this study.

**PARTICIPANT'S RIGHTS:** If you have read this form and have decided your child to participate in this research, please understand your participation is voluntary and you have the right to withdraw your consent or discontinue participation at any time without penalty or loss of benefits to which you are otherwise entitled.

The results of this research study may be presented at scientific or professional meetings or published in scientific journals. However, your identity will not be disclosed.

Thank you for your time and attention!

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright


Name of parent/guardian
Signature of parent /guardian
Name of patient
Telephone number
Name of the dentist

Signature of the dentist

For additional information regarding the trial, you can contact us at the given address, emails, or phone numbers.

## **Researchers:**

Maria Shindova, DDS, MSc, PhD Chief Assistant Professor Department of Pediatric Dentistry Faculty of Dental Medicine Medical University – Plovdiv 3 Hristo Botev Blvd 4000 Plovdiv, Bulgaria Mobile: + 359 898 390 935 mariya.shindova@gmail.com Mariya.Shindova@mu-plovdiv.bg Ani Belcheva, DDS, MSc, PhD Professor Department of Pediatric Dentistry Faculty of Dental Medicine Medical University - Plovdiv 3 Hristo Botev Blvd 4000 Plovdiv, Bulgaria Mobile: + 359 889 528 932 abeltcheva@yahoo.com



## Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

9 10 11				Page
12 13			Reporting Item	Number
14 15 16	Administrative			
17 18 19 20 21 22	information			
	Title	<u>#1</u>	Descriptive title identifying the study design, population,	1
22 23 24 25			interventions, and, if applicable, trial acronym	
26 27	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name	2
28 29			of intended registry	
30 31 32 33 34				
35 36	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	2
37 38 39 40	data set		Registration Data Set	
41 42	Protocol version	<u>#3</u>	Date and version identifier	2
43 44 45 46				
47 48 49 50	Funding	<u>#4</u>	Sources and types of financial, material, and other support	2,14
50 51 52	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	1
53 54	responsibilities:			
55 56 57 58	contributorship			
59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	2
3 4	responsibilities:			
5 6 7	sponsor contact			
7 8 9 10	information			
11 12	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study design;	13
13 14	responsibilities:		collection, management, analysis, and interpretation of data;	
15 16 17	sponsor and funder		writing of the report; and the decision to submit the report for	
18 19			publication, including whether they will have ultimate	
20 21			authority over any of these activities	
22 23	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
24 25	responsibilities:	<u>#00</u>	centre, steering committee, endpoint adjudication	n/a
26 27 28				
29	committees		committee, data management team, and other individuals or	
30 31 32 33 34			groups overseeing the trial, if applicable (see Item 21a for	
			data monitoring committee)	
35 36	Introduction			
37 38				
39 40	Background and	<u>#6a</u>	Description of research question and justification for	3,4
41 42	rationale		undertaking the trial, including summary of relevant studies	
43 44			(published and unpublished) examining benefits and harms	
45 46			for each intervention	
47 48 49	Background and	<u>#6b</u>	Explanation for choice of comparators	3,4
50 51 52	rationale: choice of			
53 54	comparators			
55 56 57 58	Objectives	<u>#7</u>	Specific objectives or hypotheses	4
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 24 of 30

1 2 3 4 5 6 7 8 9 10	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4
10 11 12	Methods:			
12 13 14	Participants,			
15 16	interventions, and			
17 18 19	outcomes			
20 21 22	Study setting	<u>#9</u>	Description of study settings (eg, community clinic,	5
22 23 24			academic hospital) and list of countries where data will be	
25 26			collected. Reference to where list of study sites can be	
27 28 29 30			obtained	
30 31 32	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable,	5,6
33 34			eligibility criteria for study centres and individuals who will	
35 36 37			perform the interventions (eg, surgeons, psychotherapists)	
38 39	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to allow	5,6
40 41 42	description		replication, including how and when they will be	
42 43 44			administered	
45 46	Interventions:	#11b	Criteria for discontinuing or modifying allocated interventions	n/a
47 48 49	modifications		for a given trial participant (eg, drug dose change in	
50 51			response to harms, participant request, or improving /	
52 53			worsening disease)	
54 55 56				
56 57 58	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention protocols,	n/a
59 60		For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	adherance		and any procedures for monitoring adherence (eg, drug	
3 4			tablet return; laboratory tests)	
5 6 7			Non-adherence interventions in the present study	
8 9 10	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that are	n/a
11 12 13	concomitant care		permitted or prohibited during the trial	
13 14 15			No permitted or prohibited during the trial concomitant care	
16 17 18			and interventions	
19 20	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the	8,9
21 22 23			specific measurement variable (eg, systolic blood pressure),	
23 24 25			analysis metric (eg, change from baseline, final value, time	
26 27			to event), method of aggregation (eg, median, proportion),	
28 29			and time point for each outcome. Explanation of the clinical	
30 31 22			relevance of chosen efficacy and harm outcomes is strongly	
32 33 34			recommended	
35 36				
37 38	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any	9
39 40			run-ins and washouts), assessments, and visits for	
41 42			participants. A schematic diagram is highly recommended	
43 44			(see Table 1)	
45 46 47	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study	9
48 49			objectives and how it was determined, including clinical and	
50 51			statistical assumptions supporting any sample size	
52 53 54			calculations	
55 56 57 58	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to	9
59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			reach target sample size	
2 3 4 5 6 7	Methods:			
	Assignment of			
, 8 9	interventions (for			
10 11	controlled trials)			
12 13 14	Allocation: sequence	<u>#16a</u>	Method of generating the allocation sequence (eg,	10
15 16	generation		computer-generated random numbers), and list of any	
17 18 19			factors for stratification. To reduce predictability of a random	
20 21			sequence, details of any planned restriction (eg, blocking)	
22 23			should be provided in a separate document that is	
24 25 26			unavailable to those who enrol participants or assign	
27 28 29 30 31 32 33			interventions	
	Allocation	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg,	10
	concealment		central telephone; sequentially numbered, opaque, sealed	
34 35	mechanism		envelopes), describing any steps to conceal the sequence	
36 37 38			until interventions are assigned	
39 40	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will enrol	10
41 42 43	implementation		participants, and who will assign participants to interventions	
44 45	Plinding (macking)	#170	Whe will be blinded ofter accimpant to interventions (or	10
46 47	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg,	10
48 49 50			trial participants, care providers, outcome assessors, data	
51 52			analysts), and how	
53 54	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	n/a
55 56	emergency		permissible, and procedure for revealing a participant's	
57 58 59	unblinding		allocated intervention during the trial	
60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3			open-label trial	
4 5	Methods: Data			
6 7	collection,			
8 9 10	management, and			
11 12	analysis			
13 14 15 16	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline,	10
17 18			and other trial data, including any related processes to	
19 20			promote data quality (eg, duplicate measurements, training	
21 22			of assessors) and a description of study instruments (eg,	
23 24			questionnaires, laboratory tests) along with their reliability	
25 26			and validity, if known. Reference to where data collection	
27 28 29 30			forms can be found, if not in the protocol	
31 32	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete follow-	10,11
33 34	retention		up, including list of any outcome data to be collected for	
35 36			participants who discontinue or deviate from intervention	
37 38 39			protocols	
40 41 42	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including	10,11
42 43 44			any related processes to promote data quality (eg, double	
45 46			data entry; range checks for data values). Reference to	
47 48			where details of data management procedures can be	
49 50 51			found, if not in the protocol	
52 53 54	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary	11
55 56			outcomes. Reference to where other details of the statistical	
57 58			analysis plan can be found, if not in the protocol	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and	11
3 4 5	analyses		adjusted analyses)	
6 7 8	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol non-	11
9 10	population and		adherence (eg, as randomised analysis), and any statistical	
10 11 12 13	missing data		methods to handle missing data (eg, multiple imputation)	
14 15 16	Methods: Monitoring			
17 18	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC); summary	12
19 20	formal committee		of its role and reporting structure; statement of whether it is	
21 22 23			independent from the sponsor and competing interests; and	
23 24 25			reference to where further details about its charter can be	
26 27			found, if not in the protocol. Alternatively, an explanation of	
28 29 30			why a DMC is not needed	
31 32 33	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping guidelines,	n/a
34 35	interim analysis		including who will have access to these interim results and	
36 37 38			make the final decision to terminate the trial	
39 40	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing	n/a
41 42			solicited and spontaneously reported adverse events and	
43 44 45			other unintended effects of trial interventions or trial conduct	
46 47 48	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any,	n/a
49 50			and whether the process will be independent from	
51 52 53			investigators and the sponsor	
54 55	Ethics and			
56 57 58	dissemination			
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Research ethics	<u>#24</u>	Plans for seeking research ethics committee / institutional	11,12
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	approval		review board (REC / IRB) approval	
	Protocol	<u>#25</u>	Plans for communicating important protocol modifications	11,12
	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
			relevant parties (eg, investigators, REC / IRBs, trial	
			participants, trial registries, journals, regulators)	
	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential	12
18 19 20			trial participants or authorised surrogates, and how (see	
20 21 22 23 24 25			Item 32)	
	Consent or assent:	<u>#26b</u>	Additional consent provisions for collection and use of	n/a
26 27	ancillary studies		participant data and biological specimens in ancillary	
28 29 30 31 32			studies, if applicable	
	Confidentiality	<u>#27</u>	How personal information about potential and enrolled	12
33 34 35			participants will be collected, shared, and maintained in	
36 37			order to protect confidentiality before, during, and after the	
38 39			trial	
40 41 42	Declaration of	<u>#28</u>	Financial and other competing interests for principal	12
43 44 45	interests		investigators for the overall trial and each study site	
45 46 47	Data access	#29	Statement of who will have access to the final trial dataset.	12
48 49 50 51 52 53 54 55 56	<u></u>	<u></u>	and disclosure of contractual agreements that limit such	
			access for investigators	
		#00		
	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for	n/a
57 58 59	trial care		compensation to those who suffer harm from trial	
60	I	For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			participation	
3 4	Dissemination	<u>#31a</u>	Plans for investigators and sponsor to communicate trial	12,13
5 6 7	policy: trial results		results to participants, healthcare professionals, the public,	
8 9			and other relevant groups (eg, via publication, reporting in	
10 11			results databases, or other data sharing arrangements),	
12 13 14			including any publication restrictions	
15 16 17	Dissemination	<u>#31b</u>	Authorship eligibility guidelines and any intended use of	12
18 19	policy: authorship		professional writers	
20 21	Dissemination	<u>#31c</u>	Plans, if any, for granting public access to the full protocol,	n/a
22 23 24	policy: reproducible		participant-level dataset, and statistical code	
25 26	research			
27 28 29 30	Appendices			
31 32 33	Informed consent	<u>#32</u>	Model consent form and other related documentation given	Suppl 1-
34 35	materials		to participants and authorised surrogates	3
36 37 38 39				
40 41	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of	n/a
42 43 44			biological specimens for genetic or molecular analysis in the	
44 45 46			current trial and for future use in ancillary studies, if	
47 48			applicable	
49 50				
51 52 53				
54 55				
56 57				
58 59	E		aview only http://bmienen.hmi.com/site/about/guidelines.yhtml	

# **BMJ Open**

## EFFICIENCY OF ER:YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS: A STUDY PROTOCOL FOR A RANDOMIZED CLINICAL TRIAL

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-054523.R2
Article Type:	Protocol
Date Submitted by the Author:	21-Jun-2022
Complete List of Authors:	Belcheva, Ani; Medicinski universitet-Plovdiv, Department of Paediatric Dentistry Shindova, Maria; Medicinski universitet-Plovdiv, Department of Paediatric Dentistry
<b>Primary Subject Heading</b> :	Dentistry and oral medicine
Secondary Subject Heading:	Dentistry and oral medicine
Keywords:	Paediatric anaesthesia < ANAESTHETICS, Laser therapy < DERMATOLOGY, Child & adolescent psychiatry < PSYCHIATRY, Anxiety disorders < PSYCHIATRY



## EFFICIENCY OF ER:YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS: A STUDY PROTOCOL FOR A RANDOMIZED CLINICAL TRIAL

## <sup>1</sup>Ani Bozhidarova Belcheva, <sup>2</sup>Maria Petrova Shindova

<sup>1</sup> DDS, PhD, MSc, Professor, Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, abeltcheva@yahoo.com, vice\_rector\_ea@mu-plovdiv.bg, ORCID iD: 0000-0002-9625-8684

<sup>2</sup> DDS, PhD, Senior Assistant Professor, Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, mariya.shindova@gmail.com, Mariya.Shindova@mu-plovdiv.bg, ORCID iD: 0000-0003-2996-3700

## **Corresponding author**

Maria Shindova, DDS, MSc, PhD Senior Assistant Professor Department of Paediatric Dentistry Faculty of Dental Medicine Medical University - Plovdiv 3 Hristo Botev Blvd 4000 Plovdiv, Bulgaria Mobile: + 359 898 390 935 email: mariya.shindova@gmail.com Mariya.Shindova@mu-plovdiv.bg

## Abstract

## Introduction

When providing dental care to children with a high level of dental anxiety, the range of approaches are divided into two sections – use of behavior management techniques (BMTs) and application of alternative methods for caries removal. In an attempt to reduce dental anxiety, they can be mixed and matched in accordance with the dentists` choice. Owing to the promoted advantages Erbium-doped Yttrium Aluminium Garnet (Er:YAG) laser turns into an ideal alternative technique for hard

dental tissue therapy in anxious pediatric patients. The aim of the study is to assess the efficacy of a modified version of the BMT Latent inhibition in combination with Er:YAG laser for achieving a reduction of dental anxiety in pediatric dental patients.

## Methods and analysis

This is a protocol for a randomized controlled clinical trial. The participants will be children aged 6-9 years, requiring conservative treatment of occlusal carious lesion on a second primary molar. Patients will be randomly assigned to the experimental or control group via a computer-generated sequence. In both groups, Latent inhibition will be used as an anxiety-management technique. In the experimental group caries treatment will be performed with Er:YAG laser, whereas in the control group with the conventional rotary instruments. Outcome measures will be dental anxiety felt before and after the treatment, reported by the patient on a modified version of Faces Scale by LeBaron and the dynamics of heart rate, registered during the treatment session, measured with a mobile pulse oximeter. Data will be analyzed by Independent sample t-test and paired t-test, p<0.05.

## Ethics and dissemination

The study protocol has been approved by the Committee for Scientific Research Ethics, Medical University-Plovdiv, Bulgaria (Reference number P-2839, Protocol of approval No. 3/30.04.2015) and registered on a publicly accessible database. This research received institutional funding from the Medical University–Plovdiv, Bulgaria. The results will be presented through peer-reviewed publications and conference presentations.

Trial registration: ClinicalTrials.gov (Registration number: NCT04924452).

Keywords: Er: YAG laser, anxiety, management technique, pediatric dentistry

## Article Summary

## Strengths and limitations of this study

- The study focuses on the implementation of a known BMT in the alternative caries treatment method
- A key strength of this study is that all participants meeting eligibility criteria will receive active treatment.

• Both subjective and objective tools are used to assess dental anxiety in this study.

- A limitation of this study is that it is not a split-mouth design whose advantage is the reduction of the outcome variability estimation
- 1. Introduction
- 1.1. Background and rationale

When providing dental care to children with a high level of dental anxiety, most pediatric dentists find the conventional rotary treatment method inefficient and uncomfortable. According to the principles of behavioral dentistry, as part of pediatric postgraduate education, the so-called `4S` principle must be adapted and modified to the individual clinical situation to provide adequate dental care to anxious pediatric patients [1]. The range of approaches can be divided into two sections – behavior management techniques, on one hand, and alternative methods for caries removal, on the other hand. In an attempt to reduce dental anxiety, they can be mixed and matched in accordance with the dentists' choice.

As it has been found for more than 20 years that lasers are effective for caries excavation, Laser pediatric dentistry has been rapidly developed. It offers total innovation and changes the conventional restorative treatment in pedodontics [2]. Owing to the promoted advantages such as minimal intervention and prevention, safety due to the low penetration depth of the laser beam, selective removal of caries lesion, lack of thermal damage, no pain perception and use of local anesthesia, a significant decrease of patient discomfort and dental anxiety and increase of subjective acceptance and tolerance of laser therapy in children, Er:YAG laser turns into an ideal laser for hard dental tissue therapy in anxious pediatric patients [2,3,4].

Based on the concepts of Minimal Invasive Dentistry (MID), the use of BMTs during the treatment of anxious children to reduce their anxiety is required [5]. Several specific BMTs are not part of the regular curricula of dental students and have been used by pediatric dentists only [4,6,7]. Such a phycological technique is Latent inhibition also known as Gradual exposure [8,9]. It involves a series of several positive non-painful – check-ups and preventive procedures, before any invasive or painful dental manipulations. Step by step the child is exposed to potential anxiety-provoking procedures or instruments, resulting in an acquaintance with the dental setting and personnel, as well as being accustomed to dental treatment. Despite the specific indications, required preparation and higher time consumption, the use of this technique is very rewarding as the pediatric patient

eventually becomes comfortable with the dental procedure and creates a feeling of ability to cope within the child [6,7,10].

Over the recent years, dentists advance in using alternative methods for caries removal as part of their everyday practice. Therefore, the investigation of this synergetic effect of laser caries removal and the different BMTs is crucial for the present and future development of pediatric dentistry and will improve the quality of dental care.

1.2. Objectives

The aim of the study is to assess the efficacy of a modified version of the BMT Latent inhibition in combination with Er:YAG laser for achieving a reduction of dental anxiety in paediatric dental patients. The main objectives are to compare dental anxiety felt during the laser and conventional dental treatment. The outcomes will be dental anxiety assessment by self-reported anxiety scale during treatment in both groups as well as the measurement of heart rate dynamics during the procedures.

## 1.3. Trial design

The research is designed as a randomized parallel-group controlled clinical study. Table 1 presents the recruiting, allocation, interventions, monitoring, and analysis of the research in accordance with the Standard Protocol Items: Recommendations for Interventional Trials recommendations [11]. In accordance with the Latent inhibition technique patients will have two visits to the dental office – a preventive procedure, the first one, and treatment of caries lesion, the second one. Two groups will be compared. In the experimental group the enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment will be performed with Er:YAG laser, whereas in the control group the conventional rotary instruments - high-speed and low-speed dental handpieces, will be used for the caries treatment.

Table 1. Trial design. The table summarises the enrolment, allocation, interventions, and assessments in the trail

		STUDY PER	IOD		
	Enrolment -t <sub>1</sub>	Allocation 0	Post-allocation		
TIMEPOINT*			t <sub>1</sub>	t <sub>2</sub>	t <sub>3</sub>
ENROLMENT					
Eligibility screening	×				
Informed consent	×				
Allocation		×			
INTERVENTIONS					
Experimental group (BMT + Laser treatment of dental caries)				×	
Control group (BMT + Caries treatment with conventional rotary instruments)				×	
ASSESSMENTS					
Self-reported dental anxiety			×		×
Heart rate	$\mathbf{O}$		-		<u> </u>

\*Post-allocation time frame: t1 - before the start of the treatment;  $t_2$  - during laser or conventional treatment;  $t_3$  - end of the treatment, before leaving the dental chair.

- 2. Methods and analyses
- 2.1. Study setting

The study setting of this research includes the Department of Paediatric Dentistry and the Laser Centre of the Faculty of Dental medicine, Medical University – Plovdiv, Bulgaria.

- 2.2. Eligibility
- 2.2.1. Inclusion criteria
  - 1. Participants in the study are children aged 6-9 years, compliant with the cognitive development of the child;
  - 2. Children, requiring conservative treatment of occlusal carious lesions on a second primary molar, without spontaneous unprovoked pain, percussion or palpation pain or other symptoms, indicating pulp involvement or periodontal pathology. Lesions are classified as

a distinct cavity with visible dentin without prior restoration or sealants by the International Caries Detection and Assessment System (ICDAS) with code 05 [12,13,14]. Included are caries lesions only on vital teeth.

- 3. Children with one or more permanent molars giving indications for pit and fissure sealing;
- 4. Patients without previous experience with laser treatment of carious lesions;
- 5. Children who are not considered medically compromised or medically complex patients;
- 6. Verbal assent from the child willing to comply with all study procedures and protocol;
- 7. Obtained written informed consent by the patient's parent/guardian for participation in the study (see supplementary data file S1 'Patient consent form' and S2 'Information leaflet').

2.2.2. Exclusion criteria

- 1. Patients who were undergoing therapy with neurological, sedative, analgesic, and/or antiinflammatory drugs 7 days prior to treatment that might affect heart rate;
- 2. Children, who were first-time dental patients;
- 3. Children with systemic diseases or physiological development delays;
- 4. Children with mental or cognitive problems;
- 5. Active infectious diseases such as influenza, scarlet fever, etc.
- 6. Excluded are molars which are affected by disturbances in the development of dental structures (hypoplasia, hypomineralization, fluorosis)

2.2.3. Interventions

Patients will be divided into 2 groups (41 per group) – experimental and control groups. All treatments will be carried out by the same operator (MS), without anesthesia. A baseline dental self-reported anxiety will be recorded using a Faces anxiety scale as well as the dynamics of heart rate, measured with a mobile pulse oximeter.

## Er: YAG laser therapy protocol (experimental group):

Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment. Chosen protocol parameters are modified based on previously conducted studies [2,3,4,15,16]:

• preventive procedure – sealant application:

Page 7 of 29

## BMJ Open

	low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for
	leaning and polishing of the occlusal surface of the chosen permanent molar;
- to	both surface will be washed for debris and organic residue removal and dried with air spray;
- is	solation with rubber dam;
- la	aser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-
ti	ssue distance 1.5mm from the tooth surface; tip diameter 600 $\mu$ m; laser energy 70 mJ; pulse
fr	requency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm <sup>2</sup> ;
- to	both surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30
S	econds and rinsed for the same time;
- to	both surface will be dried with air spray for 15s;
- fi	issure sealant application (Pit&Fisssure Sealant, DMP Ltd);
- li	ght cured for 20 seconds.
	caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm <sup>2</sup> ,
	pulse frequency 20Hz; tip diameter 800 µm; water spray level 8; tip-to-tissue distance 0.5÷1
	mm from the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm <sup>2</sup> , pulse
	frequency 20Hz; tip diameter 800 µm; water spray level 8; tip-to-tissue distance 0.5÷1 mm
	form the tooth surface. Restoration with compomer. Time for caries removal procedure – max
	8 minutes [17,18,19,20].
Con	ventional therapy protocol (control group):
	<ul> <li>preventive procedure – sealant application</li> </ul>
	low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for
c	leaning and polishing of the occlusal surface of the chosen permanent molar;
- to	both surface will be washed for debris and organic residue removal and dried with air spray;
- is	solation with rubber dam;
- to	both surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30
S	econds and rinsed for the same time;
- to	both surface will be dried with air spray for 15s;
- fi	issure sealant application (Pit&Fisssure Sealant, DMP Ltd);

- light cured for 20 seconds.

• caries removal – conventional rotary instruments will be used - high-speed and low-speed dental handpieces. For the bur preparation 1.2 mm diameter diamond round bur Drendel &

Zweiling No. 801.314. and Komet Steel round bur 016, Komet Dental Gebr were used. A new bur was used for each preparation. Restoration with compomer. Time for caries removal procedure – max 4 minutes.

2.2.4. Clinical protocol

First visit:

- 1. Parents/guardians are informed about the protocol of the study and the laser technique. They sign the informed consent form (see Supplementary data files S1 and S2). Verbal assent from the child is obtained.
- 2. Oral examination and sealant application are performed according to the assigned intervention.
- 3. Patient's self-report of dental anxiety before leaving the dental chair.

Second visit:

- Patients will be asked to report their dental anxiety, pointing to the face or choose the number which most closely depicted its state of anxiety using a modified version of the self-report Faces Scale by LeBaron et al. [21] (see Supplementary data file S3)
- 2. Pulse-oximeter is connected to the patient's index finger. The start of heart rate monitoring and recording will be 5 minutes prior to treatment. Time frame: at least 5 minutes after the dental treatment, before leaving the dental chair.
  - 3. Caries treatment is performed according to the assigned intervention.
  - 4. Patient's self-report of dental anxiety before leaving the dental chair.
- 2.3. Outcomes
- 2.3.1. Primary outcome measures

The primary outcome will be the dental anxiety before and after the treatment session, reported by the patient on a modified version of the self-report Faces Scale by LeBaron et al.. The scale comprises a row of five faces ranging from `relaxed` to `very worried` in combination with a visual analog scale of 0 - 10. Each child was asked to point to the face or choose the number which most closely depicted its state of anxiety.

2.3.2. Secondary outcome measures

The secondary outcome will be the dynamics of heart rate, registered during the treatment session measured with a mobile pulse oximeter (CMS50F, CONTEC), placed on the index finger of the left hand [22]. Throughout the whole procedure of each dental visit, data were recorded and

#### **BMJ** Open

analyzed by a specially developed digital processing and graphic visualization software SPO2 Review V1.2 rel.

2.3.3. Participant's timeline

Each eligible patient undergoes two visits. The first appointment includes screening, consenting and assenting, recording of dental anxiety, sealant application according to the assigned interventions for each group. The second appointment at the one-week recall includes a recording of dental anxiety and treatment of a carious lesion according to the assigned interventions for each group. The manipulations will be performed by one operator.

2.3.4. Sample size calculation

The sample size calculation is performed based on data from a pilot study with 20 subjects. To estimate sample size for the primary outcome—self-reported anxiety felt, according to the Faces Scale by LeBaron —a t-test for paired groups has been used (G\* Power software V.3.1,6 since we have two groups). The effect size was determined using the formula

$$ES = \frac{Control - Treated}{SDpooled} = \frac{2.33 - 0.33}{3.25} = 0.62$$

where SD is the pooled SD, an average of the SD of the experimental and control groups. The sample size is calculated to assure a test power greater than 95% and a significant level of  $\alpha = 0.05$ . We estimated a sample size of 41 patients per group to detect significant differences. Thus, the final sample size for this study will be 82 patients.

#### 2.4. Recruitment

The patients at the Department of Paediatric Dentistry of the Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, who meet the inclusion criteria, will be screened for eligibility. Once identified, patients will be informed about this research project and will receive information about the possibility of potential study participation. Patient recruitment starts obtaining the full quota of participants within a one-year time frame. It begins in September 2021 with an estimated enrollment capacity of 5 patients per month.

#### 2.5. Participating centers

The patients are randomly selected from the visitors in the Department of Paediatric Dentistry of the Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria, and treated in the Laser Centre of the same university.

- 2.6. Assignment of the intervention
- 2.6.1. Sequence generation

The patients will be randomly allocated to either the control group or the experimental group (41 patients in each group) according to the enrolment number in the trial. The randomization will be created using a computerized random generator.

2.6.2. Allocation concealment mechanism and implementation

A randomization list will be created by a random generator before the start of the treatment and kept in a locked drawer. Assignments will be kept in separate, closed opaque, sequentially numbered envelopes, enabling the sequence to be concealed until the intervention is assigned.

## 2.6.3. Blinding

The randomisation will be independent, that is, the patients and parents/guardians will remain blinded to group status. The operator will get acquainted with the procedure to be performed prior to the first session. The operator is selected to be the only one performing the manipulation to prevent bias. The statistician will be blinded to treatment assignment as data will be masked before the analysis without giving the statistician the key.

2.6.4. Data collection, confidentiality, storage, and monitoring of the study documents

Collection, coding, storage, and evaluation of personal data within the project will be carried out in accordance with The General Data Protection Regulation (EU) 2016/679 (*GDPR*). A prerequisite for data collection will be the voluntary written informed consent of the patient's parent or guardian. Confidentiality will be guaranteed by a coded ID number, access will be granted exclusively to the study investigators. The information from the paper forms will be exported to a database file and stored on a password-protected computer. Only the investigators and statistician will have access to the final data set. All data collected will be stored in sealed containers in areas of the Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria with limited access.

#### BMJ Open

### 3. Statistical methods

The obtained data will be recorded, tabulated, processed, and analyzed using SPSS (Statistical Package for Social Science software) version 21.0 (IBM, USA). In all tests, the significance level of 5% probability or the corresponding *P*-value will be adopted. Descriptive statistics will be calculated. Discrete variables will be summarised by frequencies or proportions. Continuous variables will be presented as means and standard deviations. We will compare anxiety mean scores according to the Faces Scale by LeBaron as well as heart rate mean score. Comparisons among groups will be performed by using the Independent sample t-test and paired t-test.

4. Patient and public involvement

The development of the research question and outcome measures will be based on the review of available evidence in this research area. Patients will not be involved in the development of the study protocol. However, their questions and concerns will be addressed during patient recruitment and study implementation. During the conduction of the study, patients will not be informed about the results of the ongoing trial since there is no planned interim analysis. The results will be disseminated to the study participants through email and routine follow-up dental check-ups.

5. Ethics and dissemination

The clinical study will be conducted in accordance with the conditions and principles of the Declaration of Helsinki, the existing EU Clinical Trial Directive (EC) No. 2001/20/EC, the recommendations of the Ethical Committee at the Medical University of Plovdiv, Bulgaria and the international ethical and scientific quality standard for designing, recording and reporting trials that involve the participation of human subjects - Good Clinical Practices (GCP).

5.1. Research ethics approval

The study was approved by the Committee for Scientific Research Ethics, Medical University -Plovdiv, Bulgaria (Reference number P-2839, Protocol of approval No.3/30.04.2015) and registered on a publicly accessible database ClinicalTrials.gov (Registration number: NCT04924452). Ethical approval for the study protocol and the written informed consent for all subjects` parents/guardians was granted by the Ethics Committee of the Medical University, Plovdiv, Bulgaria.

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright

## 5.2. Consent

The operators will obtain written consent from patients' parents/guardians willing to participate in the trial. Additional information will be provided for all parents for the study. Completed informed consent will be collected at the Department of Pediatric Dentistry, Medical University - Plovdiv by the study investigators. A copy of the signed consent form will be handed over to the participating child's parent/guardian. After providing age-appropriate information about the study, verbal assent will be obtained as an affirmative agreement for participation from children

## 5.3. Confidentiality

The information of the participants collected during the study will be kept strictly confidential and will not be disclosed to third parties. Confidentiality will be guaranteed by a coded ID number, access will be granted exclusively to the study investigators.

## 5.4. Conflict of interests

The investigators have no conflicts of interest to declare. They agree with the protocol and the informed consent of the study and there is no financial interest to report.

## 5.5. Access to data

All data collected will be stored in sealed containers in areas of the Department of Paediatric Dentistry, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria with limited access. The information from the paper forms will be exported to a database file and stored on a password-protected computer. Only the investigators and statistician will have access to the final data set.

5.6. Dissemination policy

The results of the trial will be presented through peer-reviewed publications and conference presentations. In addition, our results will be disseminated to clinicians, as well as key stakeholders, including scientific directors of postgraduate programs "Master of Science in Lasers in Dentistry", academic courses in Pedodontics and Preventive dentistry. The principle investigator (MS) and the scientific expert (AB) will write the first draft of the manuscript without the use of professional writers.

## Trial status

#### **BMJ** Open

The trial is not yet recruiting patients. The process will start in September 2021 and will continue until September 2022.

#### Word count: 3705

#### Acknowledgements

The authors would like to show their gratitude to Assoc. Prof. Georgi Tomov, PhD for the fruitful discussion. Assistance with the Laser Center of the Faculty of Dental Medicine, Medical University of Plovdiv, Bulgaria was greatly appreciated. The authors are also thankful to Prof. Nonka Mateva, PhD for the statistical consultancy expertise in the planning of this clinical trial.

#### **Author Contributions**

We declare that all authors have made substantial contributions. MS and AB conceive the ideas. AB trained MS. MS will be the primary operator, outcomes assessor, and data collector. All authors will participate in the analysis and reporting of the results. Writing will be led by MS. The design and protocol for this study were developed by AB and MS. All authors contributed to refining the study protocol and approving the final manuscript.

#### Funding

This research received institutional funding from the Medical University – Plovdiv, Bulgaria.

#### **Competing interests**

None declared.

#### Patient consent for publication

(see Supplementary data file S1 'Patient consent form')

### References

- Walsh LJ. Anxiety prevention: implementing the 4S principle in conservative dentistry. Auxilliary. 2007; 17; 24-26.
- Pagano S, Lombardo G, Orso M, Abraha I, Capobianco B, Cianetti S. Lasers to prevent dental caries: a systematic review. BMJ Open. 2020 Oct 28;10(10):e038638. doi: 10.1136/bmjopen-2020-038638.

- 3. Galui S, Pal S, Mahata S, Saha S, Sarkar S.Laser and its use in pediatric dentistry: A review of literature and a recent update. Int J Ped Reh 2019;4(1):1-5. DOI: 10.4103/ijpr.ijpr 17 18
- 4. American Academy of Pediatric Dentistry. Policy on the use of lasers for pediatric dental patients. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2020:116-8.
- Frencken JE, Peters MC, Manton DJ, Leal SC, Gordan VV, Eden E. Minimal intervention dentistry for managing dental caries - a review: report of a FDI task group. Int Dent J. 2012 Oct;62(5):223-43. doi: 10.1111/idj.12007.
- 6. Buldur B. Behavior Management in Pediatric Dentistry: An Overview and Interpretation.PBOCI 2019;19(1):e4649.DOI: 10.4034/PBOCI.2019.191.ed1
- Khandelwal M, Shetty RM, Rath S. Effectiveness of Distraction Techniques in Managing Pediatric Dental Patients. Int J Clin Pediatr Dent. 2019 Jan-Feb;12(1):18-24. doi: 10.5005/jpjournals-10005-1582.
- 8. Gunasekaran G,Ramakrishnan M. Evaluation of factors affecting the behaviour of uncooperative pedodontic patients. PJAEE 2020;17(7), 2027- 2038. ISSN 1567-214x.
- Subramaniam P, Haqh M, Gupta M.Assessment of trait and state anxiety in 3-6-year old children during sequential phases of dental treatment. Contemp Pediatr Dent 2020:1(1):22-32. DOI: 10.51463/cpd.2020.10
- 10. Tajadura-Jimenez A, Grehl S, Tsakiris M. The other in me: Interpersonal multisensory stimulation changes the mental representation of the self.PLoS ONE. 2012;7.
- Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-207. doi: 10.7326/0003-4819-158-3-201302050-00583. PMID: 23295957; PMCID: PMC5114123.
- Ismail AI, Sohn W, Tellez M, Amaya A, Sen A, Hasson H, Pitts NB. The International Caries Detection and Assessment System (ICDAS): an integrated system for measuring dental caries. Community Dent Oral Epidemiol. 2007 Jun;35(3):170-8. doi: 10.1111/j.1600-0528.2007.00347.x.

13.	International Caries Detection and Assessment System (ICDAS) Coordinating Committee
	Rationale and Evidence for the International Caries Detection and Assessment System
	(ICDAS II). 2011 Sept. Available from: http://www.icdas.org.
4.	Pitts N. "Pitts N. "ICDAS"an international system for caries detection and assessment being
	developed to facilitate caries epidemiology, research and appropriate clinical management
	Community Dent Health. 2004 Sep;21(3):193-8. PMID: 15470828.
5.	Yilmaz H, Keles S. The effect of the Er: YAG laser on the clinical success of hydrophilic
	fissure sealant: a randomized clinical trial. Eur Oral Res. 2020;54(3):148-153
	doi:10.26650/eor.20200029
6.	Rattanacharoenthum A, Na-Lamphun P, Kantrong N. Altered adhesion of dental sealant to
	tooth enamel microscopically modified by Er:YAG laser irradiation: An in vitro study. Laser
	Ther. 2019;28(1):19-25. doi:10.5978/islsm.28_19-OR-02
7.	Sarmadi R, Andersson EV, Lingström P, Gabre P. A Randomized Controlled Trial Comparing
	Er:YAG Laser and Rotary Bur in the Excavation of Caries - Patients' Experiences and the
	Quality of Composite Restoration. Open Dent J 2018;12:443-454
	doi:10.2174/1874210601812010443.
8.	Li T, Zhang X, Shi H, Ma Z, Lv B, Xie M. Er: YAG laser application in caries removal and
	cavity preparation in children: a meta-analysis. Lasers Med Sci 2018. doi:10.1007/s10103-
	018-2582-x
9.	Johar S, Goswami M, Kumar G, Dhillon JK. Caries removal by Er, Cr: YSGG laser and Air
	rotor handpiece comparison in primary teeth treatment: an in vivo study. Laser Ther
	2019;28(2):116-122. doi:10.5978/islsm.19-OR-08.
0.	Montedori A, Abraha I, Orso M, D'Errico PG, Pagano S, Lombardo G. Lasers for caries
	removal in deciduous and permanent teeth. Cochrane Database Syst Rev
	2016;9(9):CD010229. doi:10.1002/14651858.CD010229.pub2
21.	LeBaron S, Zeltzer L. Assessment of acute pain and anxiety in children and adolescents by
	self-reports, observer reports, and a behavior checklist. J Consult Clin Psychol 1984; 52:729
	38. DOI: 10.1037//0022-006x.52.5.729
22.	Song JS, Chung HC, Sohn S, Kim YJ. Effects of psychological behaviour managemen
	programme on dental fear and anxiety in children: A randomised controlled clinical trial. Eu

BMJ

# **Consent form**

Nar	me of patient:	
Pat	ient`s parent/guardian:	
chil	terial – text (information about your ld`s oral health, level of dental kiety and dynamics of heart rate):	
	visional title of article in which Material I be included:	Efficacy of Combined Er:YAG Laser Therapy and Behaviour Management Technique in Reducing Anxiety among Paediatric Dental Patients
	9	CONSENT
onfirm	about my child to appear in a BMJ publica	
onfirm	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to am legally entitled to give this consent.	out my child
onfirm	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to	out my child
onfirm	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published witho	out my child
ndersta	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published witho complete anonymity cannot be gua recognise my child. The Material may show or include of	but my child BMJ but my child`s name attached, however I understand
ndersta	that I: (please tick boxes to confirm) have seen the text or other material abo have read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published witho complete anonymity cannot be gua recognise my child. The Material may show or include of prognosis, treatment or surgery that I here article may be published in a jour	out my child BMJ out my child`s name attached, however I understand ranteed. It is possible that somebody somewhere details of my child's medical condition or injury an
ndersta	that I: (please tick boxes to confirm) have seen the text or other material abore have read the article to be submitted to am legally entitled to give this consent. and the following: The Material will be published witho complete anonymity cannot be gua recognise my child. The Material may show or include of prognosis, treatment or surgery that I he The article may be published in a jour mainly to doctors and other healthcar academics, students and journalists.	ation. out my child BMJ but my child's name attached, however I understand aranteed. It is possible that somebody somewhere details of my child's medical condition or injury an have/the patient has, had or may have in the future. Irrnal which is distributed worldwide. BMJ's publication re professionals but are also seen by many others inclu- ty be the subject of a press release, and may be linked to notional activities. Once published, the article will be p

Б	M	
		/

- (7) The article may also be used in full or in part in other publications and products published by BMJ and/or by other publishers. This includes publication in English and in translation, in print, in digital formats, and in any other formats that may be used by BMJ or other publishers now and in the future. The article may appear in local editions of journals or other publications, published in the UK and overseas.
- (8) I can revoke my consent at any time before publication, but once the article has been committed to publication ("gone to press") it will not be possible to revoke the consent.
- (9) This consent form will be retained securely and in confidence by BMJ in accordance with the law, for no longer than necessary. Personal data provided in this form will be used and retained in accordance with BMJ's Privacy Policy available at https://www.bmj.com/company/your-privacy/.

Signed:	Print name:
Address:	Email address:
	Telephone no:
* signing on behalf of the patient who is under the	e age of 18
`Q	Date:
Corresponding author	
Signed:	Author`s name: Maria Shindova
Position: Senior Assistant Professor	Address: 3 Hristo Botev Bulv., Plovdiv, Bulgaria
Institution: Department of Pediatric	
Dentistry, Faculty of Dental Medicine,	
Medical University of Plovdiv	2
Email address: mariya.shindova@gmail.com	Telephone no: + 359 898 390 935
Date:	

## **INFORMATION LEAFLET**

**BMJ** Open

## DEPARTMENT OF PAEDIATRIC DENTISTRY LASER CENTER FACULTY OF DENTAL MEDICINE, MEDICAL UNIVERSITY OF PLOVDIV, BULGARIA

## EFFICIENCY OF ER:YAG LASER THERAPY IN COMBINATION WITH BEHAVIOUR MANAGEMENT TECHNIQUE IN REDUCING ANXIETY AMONG PAEDIATRIC DENTAL PATIENTS

**DESCRIPTION:** You and your child are invited to participate in a research study on the efficiency of Er:YAG laser therapy in combination with behavior management technique in reducing anxiety among pediatric dental patients.

**PROCEDURES:** With your permission, we would like to collect information about your children's dental anxiety before, during and after dental treatment of a caries lesion. This study does not involve any experiments, just preventive procedures and dental treatment, collection, and study of the required information.

**RISKS AND BENEFITS:** There are no anticipated risks associated with this study. You will not receive any direct benefit from participation.

**TIME INVOLVEMENT:** Your child's participation in this study will not require more time from you other than for the first visit including an explanation of the study, oral examination and a preventive procedure (sealant application). The second appointment at 7-day recall will include dental treatment.


**PAYMENTS:** You will not be paid to participate in this study. You will not pay for the treatment of your child in this study.

**PARTICIPANT'S RIGHTS:** If you have read this form and have decided your child to participate in this research, please understand your participation is voluntary and you have the right to withdraw your consent or discontinue participation at any time without penalty or loss of benefits to which you are otherwise entitled.

The results of this research study may be presented at scientific or professional meetings or published in scientific journals. However, your identity will not be disclosed.

Thank you for your time and attention!

1		
2		
3 4	Name of parent/guardian	
5 6 7	Signature of parent /guardian	
7 8 9	Name of patient	
10 11	Telephone number	
12		
13 14	Name of the dentist	
14		
16	Signature of the dentist	
17	Signature of the dentise	
18		
19	For additional information regarding the trial, you can co	ntact us at the given address, emails, or
20		intact us at the given address, emans, or
21	phone numbers.	
22	Descendence	
23	Researchers:	
24 25	Maria Shindova, DDS, MSc, PhD	Ani Belcheva, DDS, MSc, PhD
25	Chief Assistant Professor	Professor
27	Department of Pediatric Dentistry	Department of Pediatric Dentistry
28	Faculty of Dental Medicine	Faculty of Dental Medicine
29	Medical University – Plovdiv	Medical University - Plovdiv
30	3 Hristo Botev Blvd	3 Hristo Botev Blvd
31	4000 Plovdiv, Bulgaria	4000 Plovdiv, Bulgaria
32	Mobile: + 359 898 390 935	Mobile: + 359 889 528 932
33	mariya.shindova@gmail.com	abeltcheva@yahoo.com
34	Mariya.Shindova@mu-plovdiv.bg	
35 36		
30		
38		
39		
40		
41		
42		
43		
44 45		
43 46		
47		
48		
49		
50		
51		
52		
53		
54 55		
55 56		
57		
58		
59		
60	For peer review only - http://bmjopen.bmj.com/	/site/about/guidelines.xhtml



Based on the SPIRIT guidelines.					
			Page		
		Reporting Item	Numbe		
Administrative					
information					
Title	<u>#1</u>	Descriptive title identifying the study design, population,	1		
		interventions, and, if applicable, trial acronym			
Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name	2		
		of intended registry			
Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	2		
data set		Registration Data Set Date and version identifier			
Protocol version	<u>#3</u>	Date and version identifier	2		
Funding	<u>#4</u>	Sources and types of financial, material, and other support	2,14		
Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	1		
responsibilities:					
contributorship					

1 2	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	2
3 4	responsibilities:			
5 6 7	sponsor contact			
7 8 9 10 11 12	information			
	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study design;	13
13 14	responsibilities:		collection, management, analysis, and interpretation of data;	
15 16 17	sponsor and funder		writing of the report; and the decision to submit the report for	
18 19			publication, including whether they will have ultimate	
20 21 22			authority over any of these activities	
23 24	Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating	n/a
25 26	responsibilities:		centre, steering committee, endpoint adjudication	
27 28 29	committees		committee, data management team, and other individuals or	
30 31			groups overseeing the trial, if applicable (see Item 21a for	
32 33			data monitoring committee)	
34 35 36	Introduction			
37 38				
39 40	Background and	<u>#6a</u>	Description of research question and justification for	3,4
41 42	rationale		undertaking the trial, including summary of relevant studies	
43 44			(published and unpublished) examining benefits and harms	
45 46			for each intervention	
47 48 49	Background and	<u>#6b</u>	Explanation for choice of comparators	3,4
50 51 52	rationale: choice of			
52 53 54 55	comparators			
55 56 57 58	Objectives	<u>#7</u>	Specific objectives or hypotheses	4
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel	4
3 4			group, crossover, factorial, single group), allocation ratio,	
5 6 7			and framework (eg, superiority, equivalence, non-inferiority,	
7 8 9			exploratory)	
10 11				
12 13	Methods:			
14 15	Participants,			
16 17	interventions, and			
18 19	outcomes			
20 21 22	Study setting	<u>#9</u>	Description of study settings (eg, community clinic,	5
23 24			academic hospital) and list of countries where data will be	
25 26			collected. Reference to where list of study sites can be	
27 28 29			obtained	
30 31	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	5,6
32 33	Englority criteria	<u>#10</u>		5,0
34 35			eligibility criteria for study centres and individuals who will	
36 37			perform the interventions (eg, surgeons, psychotherapists)	
38 39 40	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to allow	5,6
41 42	description		replication, including how and when they will be	
43 44			administered	
45 46 47	Interventions:	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions	n/a
48 49	modifications		for a given trial participant (eg, drug dose change in	
50 51			response to harms, participant request, or improving /	
52 53			worsening disease)	
54 55				
56 57 58	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention protocols,	n/a
58 59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright.

1	adherance		and any procedures for monitoring adherence (eg, drug	
2 3 4 5 6 7 8 9 10 11 12			tablet return; laboratory tests)	
			Non-adherence interventions in the present study	
	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that are	n/a
	concomitant care		permitted or prohibited during the trial	
13 14 15			No permitted or prohibited during the trial concomitant care	
16 17 18			and interventions	
19 20	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the	8,9
21 22 23			specific measurement variable (eg, systolic blood pressure),	
24 25			analysis metric (eg, change from baseline, final value, time	
26 27			to event), method of aggregation (eg, median, proportion),	
28 29 30			and time point for each outcome. Explanation of the clinical	
30 31 32			relevance of chosen efficacy and harm outcomes is strongly	
33 34			recommended	
35 36 37	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any	9
38 39			run-ins and washouts), assessments, and visits for	
40 41 42			participants. A schematic diagram is highly recommended	
43 44			(see Table 1)	
45 46 47	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study	9
48 49			objectives and how it was determined, including clinical and	
50 51 52			statistical assumptions supporting any sample size	
53 54			calculations	
55 56 57 58	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to	9
59 60		For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			reach target sample size	
3 4 5 6 7 8 9 10 11	Methods:			
	Assignment of			
	interventions (for			
	controlled trials)			
12 13 14	Allocation: sequence	<u>#16a</u>	Method of generating the allocation sequence (eg,	10
15 16	generation		computer-generated random numbers), and list of any	
17 18 19			factors for stratification. To reduce predictability of a random	
20 21			sequence, details of any planned restriction (eg, blocking)	
22 23			should be provided in a separate document that is	
24 25 26			unavailable to those who enrol participants or assign	
27 28			interventions	
29 30 31	Allocation	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg,	10
32 33	concealment		central telephone; sequentially numbered, opaque, sealed	
34 35	mechanism		envelopes), describing any steps to conceal the sequence	
36 37 38			until interventions are assigned	
39 40	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	10
41 42	implementation	<u>// 100</u>	participants, and who will assign participants to interventions	10
43 44	Implementation		participanto, and who will assign participanto to interventions	
45 46 47	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg,	10
48 49			trial participants, care providers, outcome assessors, data	
50 51			analysts), and how	
52 53 54	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	n/a
54 55 56	emergency		permissible, and procedure for revealing a participant's	
57 58	unblinding		allocated intervention during the trial	
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3			open-label trial	
4 5 6 7	Methods: Data			
	collection,			
8 9 10	management, and			
11 12	analysis			
13 14 15 16 17 18	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to	10
19 20			promote data quality (eg, duplicate measurements, training	
21 22			of assessors) and a description of study instruments (eg,	
23 24			questionnaires, laboratory tests) along with their reliability	
25 26 27			and validity, if known. Reference to where data collection	
28 29 30			forms can be found, if not in the protocol	
31 32	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete follow-	10,11
33 34	retention		up, including list of any outcome data to be collected for	
35 36 27			participants who discontinue or deviate from intervention	
37 38 39			protocols	
40 41 42	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including	10,11
42 43 44			any related processes to promote data quality (eg, double	
45 46			data entry; range checks for data values). Reference to	
47 48			where details of data management procedures can be	
49 50			found, if not in the protocol	
51 52 53		1100		4.4
54 55	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary	11
56 57			outcomes. Reference to where other details of the statistical	
58 59			analysis plan can be found, if not in the protocol	
60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and	11
3 4 5	analyses		adjusted analyses)	
6 7 0	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol non-	11
8 9 10	population and		adherence (eg, as randomised analysis), and any statistical	
11 12 13	missing data		methods to handle missing data (eg, multiple imputation)	
14 15 16	Methods: Monitoring			
17 18	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC); summary	12
19 20	formal committee		of its role and reporting structure; statement of whether it is	
21 22 23			independent from the sponsor and competing interests; and	
23 24 25			reference to where further details about its charter can be	
26 27			found, if not in the protocol. Alternatively, an explanation of	
28 29 30			why a DMC is not needed	
31 32 33	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping guidelines,	n/a
33 34 35	interim analysis		including who will have access to these interim results and	
36 37 38			make the final decision to terminate the trial	
39 40	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing	n/a
41 42 42			solicited and spontaneously reported adverse events and	
43 44 45 46			other unintended effects of trial interventions or trial conduct	
40 47 48	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any,	n/a
49 50			and whether the process will be independent from	
51 52 53			investigators and the sponsor	
54 55 56	Ethics and			
56 57 58	dissemination			
59 60	I	For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2021-054523 on 5 September 2022. Downloaded from http://bmjopen.bmj.com/ on June 29, 2024 by guest. Protected by copyright.

1 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 12 2 3 4 5 6 7 8 9 0 12 2 3 4 5 6 7 8 9 0 12 2 3 4 5 6 7 8 9 0 12 2 3 3 4 5 6 7 8 9 0 12 2 3 4 5 5 6 7 8 9 0 12 2 3 3 4 5 5 6 7 8 9 0 12 2 3 4 5 5 6 7 8 9 0 12 2 3 4 5 5 6 7 8 9 0 12 2 3 4 5 5 6 7 8 9 0 12 2 3 4 5 5 6 7 8 9 0 1 2 5 5 8 9 0 1 2 5 5 8 9 0 1 2 5 5 8 9 0 1 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Research ethics	<u>#24</u>	Plans for seeking research ethics committee / institutional	11,12
	approval		review board (REC / IRB) approval	
	Protocol	<u>#25</u>	Plans for communicating important protocol modifications	11,12
	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
			relevant parties (eg, investigators, REC / IRBs, trial	
			participants, trial registries, journals, regulators)	
	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential	12
			trial participants or authorised surrogates, and how (see	
			Item 32)	
	Consent or assent:	<u>#26b</u>	Additional consent provisions for collection and use of	n/a
	ancillary studies		participant data and biological specimens in ancillary	
			studies, if applicable	
	Confidentiality	<u>#27</u>	How personal information about potential and enrolled	12
			participants will be collected, shared, and maintained in	
			order to protect confidentiality before, during, and after the	
			trial	
	Declaration of	<u>#28</u>	Financial and other competing interests for principal	12
	interests		investigators for the overall trial and each study site	
	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset,	12
			and disclosure of contractual agreements that limit such	
			access for investigators	
	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for	n/a
	trial care		compensation to those who suffer harm from trial	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			participation	
3 4 5 6 7 8 9	Dissemination	<u>#31a</u>	Plans for investigators and sponsor to communicate trial	12,13
	policy: trial results		results to participants, healthcare professionals, the public,	
			and other relevant groups (eg, via publication, reporting in	
10 11			results databases, or other data sharing arrangements),	
12 13 14 15 16 17			including any publication restrictions	
	Dissemination	<u>#31b</u>	Authorship eligibility guidelines and any intended use of	12
17 18 19	policy: authorship		professional writers	
20 21	Dissemination	#31c	Plans, if any, for granting public access to the full protocol,	n/a
22 23 24	policy: reproducible		participant-level dataset, and statistical code	
24 25 26	research			
27 28 29 30 31 32 33	Appendices			
	Informed consent	<u>#32</u>	Model consent form and other related documentation given	Suppl 1-
33 34 35	materials		to participants and authorised surrogates	3
36 37 38 39				
40 41	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of	n/a
42 43			biological specimens for genetic or molecular analysis in the	
44 45 46			current trial and for future use in ancillary studies, if	
47 48			applicable	
49 50 51				
52 53				
54 55				
56 57 58				
59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml			